<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        101-15-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ONGLYZA 2.5 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SAXAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca Pharmaceuticals LP" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca Pharmaceuticals LP
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca AB 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What is ONGLYZA?</strong></p><ul><li>&nbsp;ONGLYZA is a prescription medicine used with diet and exercise to control high blood sugar (hyperglycemia) in adults with type 2 diabetes.</li><li>&nbsp;ONGLYZA lowers blood sugar by helping the body increase the level of insulin after meals.</li><li>&nbsp;ONGLYZA is unlikely by itself to cause your blood sugar to be lowered to a dangerous level (hypoglycemia) because it does not work well when your blood sugar is low. However, hypoglycemia may still occur with ONGLYZA. Your risk for getting hypoglycemia is higher if you take ONGLYZA with some other diabetes medicines, such as a sulfonylurea or insulin.</li><li>&nbsp;ONGLYZA is not for people with type 1 diabetes.</li><li>&nbsp;ONGLYZA is not for people with diabetic ketoacidosis (increased ketones in your blood or urine).</li><li>&nbsp;If you have had pancreatitis in the past, it is not known if you have a higher chance of getting pancreatitis while you take ONGLYZA.</li></ul><p>It is not known if ONGLYZA is safe and effective in children younger than 18 years old.<br /><strong>General information about the use of ONGLYZA</strong></p><p>Medicines are sometimes prescribed for conditions that are not mentioned in patient leaflets. Do not<br />use ONGLYZA for a condition for which it was not prescribed. Do not give ONGLYZA to other<br />people, even if they have the same symptoms you have. It may harm them.<br />This patient leaflet summarizes the most important information about ONGLYZA. If you would like to<br />know more information about ONGLYZA, talk with your healthcare provider. You can ask your<br />healthcare provider for additional information about ONGLYZA that is written for healthcare<br />professionals.<br /><strong>What is type 2 diabetes?</strong><br />Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that<br />your body produces does not work as well as it should. Your body can also make too much sugar.<br />When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems.<br />The main goal of treating diabetes is to lower your blood sugar so that it is as close to normal as<br />possible.<br />High blood sugar can be lowered by diet and exercise, and by certain medicines when necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take ONGLYZA if you:</strong></p><ul><li>&nbsp;are allergic to any ingredients in ONGLYZA. Please see section 6 &ldquo;Contents of the pack and other information&rdquo;)</li><li>&nbsp;if you have had a serious allergic reaction to any other similar medicines that you take to control your blood sugar. See section 4. Symptoms of a serious allergic reaction to ONGLYZA may include:</li><li>&nbsp;swelling of your face, lips, throat, and other areas on your skin</li><li>&nbsp;difficulty with swallowing or breathing</li><li>&nbsp;raised, red areas on your skin (hives)</li><li>&nbsp;skin rash, itching, flaking, or peeling</li></ul><p>If you have these symptoms, stop taking ONGLYZA and contact your healthcare provider right<br />away.<br /><strong>Take Special care with Onglyza:</strong><br />Tell your healthcare provider if you have ever had</p><ul><li>&nbsp;inflammation of your pancreas (pancreatitis)</li><li>&nbsp;stones in your gallbladder (gallstones)</li><li>a history of alcoholism</li><li>high blood triglyceride levels</li></ul><p>It is not known if having these medical problems will make you more likely to get pancreatitis with<br />ONGLYZA.<br />Stop taking ONGLYZA and contact your healthcare provider right away if you have pain in your<br />stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your<br />abdomen through to your back. The pain may happen with or without vomiting. These may be<br />symptoms of pancreatitis.<br />Before you take ONGLYZA, tell your healthcare provider if you:</p><ul><li>&nbsp;have kidney problems.</li></ul><p><strong>Children and adolescents</strong><br />Onglyza is not recommended for children and adolescents under 18 years. It is not known if<br />ONGLYZA is safe and effective in children younger than 18 years old.</p><p><strong>Tell your healthcare provider about all the medicines you take</strong> including prescription and nonprescription<br />medicines, vitamins, and herbal supplements.<br />Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider<br />and pharmacist when you get a new medicine.<br />ONGLYZA may affect the way other medicines work, and other medicines may affect how<br />ONGLYZA works. Contact your healthcare provider if you will be starting or stopping certain other<br />types of medications, such as antibiotics, or medicines that treat fungus or HIV/AIDS, because your<br />dose of ONGLYZA might need to be changed.<br /><strong>Pregnancy and breast-feeding</strong><br />Before you take ONGLYZA, tell your healthcare provider if you:</p><ul><li>&nbsp;are pregnant or plan to become pregnant. It is not known if ONGLYZA will harm your unborn baby. If you are pregnant, talk with your healthcare provider about the best way to control your blood sugar while you are pregnant.</li><li>&nbsp;are breast-feeding or plan to breast-feed. ONGLYZA may be passed in your milk to your baby. Talk with your healthcare provider about the best way to feed your baby while you take ONGLYZA.</li></ul><p><strong>Driving and using machines</strong><br />If you feel dizzy while taking Onglyza, do not drive or use any tools or machines. Hypoglycaemia<br />may affect your ability to drive and use machines or work with safe foothold and there is a risk of<br />hypoglycaemia when taking this medicine in combination with medicines known to cause<br />hypoglycaemia such as insulin and sulphonylureas.</p><p><strong>Onglyza contains lactose</strong><br />The tablets contain lactose (milk sugar). If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How should I take ONGLYZA?</strong></p><ul><li>&nbsp;Take ONGLYZA by mouth one time each day exactly as directed by your healthcare provider. Do not change your dose without talking to your healthcare provider.</li><li>&nbsp;ONGLYZA can be taken with or without food.</li><li>&nbsp;Do not split or cut ONGLYZA tablets.</li><li>&nbsp;During periods of stress on the body, such as:</li><li>&nbsp;fever</li><li>&nbsp;trauma</li><li>&nbsp;infection</li><li>&nbsp;surgery</li></ul><p>Contact your healthcare provider right away as your medication needs may change.</p><ul><li>&nbsp;Your healthcare provider should test your blood to measure how well your kidneys are working before and during your treatment with ONGLYZA. You may need a lower dose of ONGLYZA if your kidneys are not working well.</li><li>&nbsp;Follow your healthcare provider&rsquo;s instructions for treating blood sugar that is too low (hypoglycemia). Talk to your healthcare provider if low blood sugar is a problem for you.</li><li>&nbsp;Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</li></ul><p><strong>If you take more Onglyza than you should</strong><br />If you take too much ONGLYZA, call your healthcare provider or a poison control center, or go to the<br />nearest hospital emergency room right away.<br /><strong>If you forget to take Onglyza</strong><br />If you miss a dose of ONGLYZA, take it as soon as you remember. If it is almost time for your next<br />dose, skip the missed dose. Just take the next dose at your regular time. Do not take two doses at the<br />same time unless your healthcare provider tells you to do so. Talk to your healthcare provider if you<br />have questions about a missed dose.<br /><strong>If you stop taking Onglyza</strong><br />Keep taking Onglyza until your doctor tells you to stop. This is to help keep your blood sugar under<br />control.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>What is the most important information I should know about ONGLYZA?<br />Serious side effects can happen to people taking ONGLYZA,</strong> including inflammation of the<br />pancreas (pancreatitis) which may be severe and lead to death.<br />Certain medical problems make you more likely to get pancreatitis.<br /><strong>ONGLYZA can cause serious side effects, including:</strong></p><ul><li>&nbsp;<strong>See &ldquo;What is the most important information I should know about ONGLYZA?&rdquo;</strong></li><li><strong>&nbsp;Allergic (hypersensitivity) reactions,</strong> such as:</li><li>&nbsp;swelling of your face, lips, throat, and other areas on your skin</li><li>&nbsp;difficulty with swallowing or breathing</li><li>&nbsp;raised, red areas on your skin (hives)</li><li>&nbsp;skin rash, itching, flaking, or peeling</li></ul><p>If you have these symptoms, stop taking ONGLYZA and contact your healthcare provider right<br />away.</p><ul><li>&nbsp;<strong>Joint pain.</strong> Some people who take medicines called DPP-4 inhibitors like ONGLYZA, may develop joint pain that can be severe. Call your healthcare provider if you have severe joint pain.</li></ul><p><strong>Common side effects of ONGLYZA include:</strong></p><ul><li>&nbsp;upper respiratory tract infection</li><li>&nbsp;urinary tract infection</li><li>&nbsp;headache</li></ul><p><strong>Low blood sugar (hypoglycemia)</strong> may become worse in people who also take another medication to<br />treat diabetes, such as sulfonylureas or insulin. Tell your healthcare provider if you take other diabetes<br />medicines. If you have symptoms of low blood sugar, you should check your blood sugar and treat if<br />low, then call your healthcare provider. Symptoms of low blood sugar include:</p><ul><li>&nbsp;shaking</li><li>&nbsp;sweating</li><li>&nbsp;rapid heartbeat</li><li>&nbsp;change in vision</li><li>&nbsp;hunger</li><li>&nbsp;headache</li><li>&nbsp;change in mood</li></ul><p><strong>Swelling or fluid retention</strong> in your hands, feet, or ankles (peripheral edema) may become worse in<br />people who also take a thiazolidinedione to treat diabetes. If you do not know whether you are already<br />on this type of medication, ask your healthcare provider.<br />These are not all of the possible side effects of ONGLYZA.<br />Reporting of side effects<br /><strong>If you get any side effects, </strong>talk to your doctor, pharmacist or nurse. This includes any possible side<br />effects not listed in this leaflet. You can also report side effects directly (see details below). By<br />reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.<br />- Do not store above 30&deg;C.<br />- Do not use this medicine after the expiry date which is stated on the blister and the carton after<br />EXP. The expiry date refers to the last day of that month.<br />- Do not use this medicine if the package is damaged or shows signs of tampering.<br />- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to throw away medicines you no longer use. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Active ingredient: saxagliptin<br />- Inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium,<br />and magnesium stearate. In addition, the film coating contains the following inactive ingredients:<br />polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, and iron oxides.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 2.5 mg film-coated tablets are pale yellow to light yellow, biconvex, round. They have
“2.5” printed on one side and “4214” printed on the other side, in blue ink.
5 mg film-coated tablets are pink, biconvex, round. They have “5” printed on one side
and“4215” printed on the other side, in blue ink.
 2.5 mg tablets are available in pack sizes of 30x1 film-coated tablets in Bottle.
 5 mg tablets are available in pack sizes of 30x1 film-coated tablets in Bottle.
Not all pack sizes may be marketed in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:<br />SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)<br />P.O. Box 5132, Riyadh 11422, Saudi Arabia</p><p>Manufactured by:<br />AstraZeneca Pharmaceuticals LP<br />4601 Highway 62 East<br />Mount Vernon, Indiana 47620, USA<br />Marketed by: AstraZeneca</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><div style="direction: rtl;"><strong><span style="text-align:unset">ما هو أونجليزا؟</span></strong></div><ul dir="rtl"><li><span style="text-align:unset">أونجليزا هو دواء يجب تناوله مصحوب اً بنظام غذائي وتمارين رياضية للسيطرة على ارتفاع مستوى السكر في الدم (فرط سكر&nbsp;الدم) لدى المرضى البالغين المصابين بالسكري من النوع الثاني ( ٢)</span></li><li><span style="text-align:unset">يقلل أونجليزا مستوى السكر في الدم من خلال مساعدة الجسم على زيادة مستوى الأنسولين بعد تناول الوجبات.&nbsp;</span></li><li><span style="text-align:unset">من غير المحتمل أن يسبب أونجليزا في حد ذاته خفض مستوى السكر في الدم لديك إلى مستويات خطرة (نقص سكر الدم) لأنه لا&nbsp;يعمل بشكل جيد عندما يكون مستوى السكر في الدم لديك منخفضاً. إلّا أن نقص السكر في الدم قد يحدث عند تناول أونجليزا. يزداد خطر الإصابة بنقص سكر الدم بصورة أكبر في حال تناول أونجليزا مع بعض أدوية السكري الأخرى مثل السلفونيل يوريا أو الأنسولين.</span></li><li><span style="text-align:unset">&nbsp;أونجليزا غير مخصص للمصابين بمرض السكري من النوع الأول (1)</span></li><li><span style="text-align:unset">أونجليزا غير مخصص للمصابين بالحماض الكيتوني السكري (زيادة الكيتونات في الدم أو البول).&nbsp;</span></li><li><span style="text-align:unset">إذا أصِبتَ في الماضي بالتهاب البنكرياس، ليس من المعروف ما إذا كنت أكثر عُرضة للإصابة بالتهاب البنكرياس أثناء تناول&nbsp;أونجليزا.</span></li></ul><div style="direction: rtl;"><span style="text-align:unset">غير معروف ما إذا كان تناول أونجليزا آمن اً وفعالا للأطفال دون سن ١٨ عاماً.</span></div><div style="direction: rtl;">&nbsp;</div><div style="direction: rtl;"><strong>معلومات عامة حول استخدام أونجليزا</strong><br />في بعض الأوقات، تُوصف الأدوية لأمراض لا تكون مذكورة في نشرات المريض. لا تستخدم أونجليزا لعلاج مرض لم يوصف<br />لعلاجه. لا تعطِ أونجليزا للآخرين، حتى إذا كانوا يعانون نفس الأعراض التي تعاني منها. فقد يتسبب ذلك في حدوث ضرر لهم.<br />تلخص نشرة المريض هذه أهم المعلومات المتعلقة بأونجليزا. إذا كنت ترغب في مزيد من المعلومات عن أونجليزا، فتحدث مع مقدم<br />الرعاية الصحية الخاص بك. بإمكانك أن تطلب إلى مقدم الرعاية الصحية الخاص بك مزيد اً من المعلومات المقدمة لاختصاصيي<br />الرعاية الصحية عن أونجليزا.</div><div style="direction: rtl;">&nbsp;</div><div style="direction: rtl;"><strong>ما هو مرض السكري من النوع الثاني ( ٢)</strong><br />مرض السكري من النوع الثاني ( ٢) هو مرض يؤدي إلى عدم إنتاج الجسم كميات كافية من الأنسولين، فضلا عن إنه يجعل الأنسولين<br />الذي ينتجه الجسم لا يقوم بدوره كما يجب. كما من الممكن أن ينتج جسمك كميات كبيرة من السكر. عندما يحدث ذلك، يتراكم السكر<br />(الجلوكوز) في الدم. ومن الممكن أن يؤدي ذلك إلى مشاكل طبية خطرة.<br />يتمثل هدف علاج مرض السكري الرئيس في خفض مستوى السكر في الدم بحيث يقارب المستوى الطبيعي قدر الإمكان.<br />بالإمكان تخفيض مستويات السكر المرتفعة في الدم من خلال اتباع نظام غذائي وممارسة التمارين الرياضية، ومن خلال تناول أدوية<br />معينة إذا لزم الأمر.</div><div style="direction: rtl;">&nbsp;</div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><div style="direction: rtl;"><strong><span style="text-align:unset">لا تتناول أونجليزا في الحالات التالية:</span></strong></div><div style="direction: rtl;"><strong><span style="text-align:unset">إذا كنت تعاني حساسية لأيّ من مكونات أونجليزا. (يُرجى مراجعة القسم ٦ &quot;محتويات العبوة ومعلومات أخرى&quot;)&nbsp;</span></strong></div><div style="direction: rtl;"><span style="text-align:unset">. إذا كنت تعاني رد فعل حساسي خطر لأيّ أدوية أخرى مماثلة تتناولها للتحكم في مستوى السكر في الدم. انظر القسم ٤&nbsp;</span></div><div style="direction: rtl;"><span style="text-align:unset">يمكن أن تشمل أعراض ردّ الفعل الحساسي الخطير على أونجليزا ما يلي:</span></div><ul dir="rtl"><li><span style="text-align:unset">تورم الوجه، والشفتين، والحلق، ومناطق أخرى على البشرة&nbsp;</span></li><li><span style="text-align:unset">صعوبة في البلع أو التنفس&nbsp;</span></li><li><span style="text-align:unset">مناطق حمراء، مرتفعة عن الجلد (شَرَىَ)&nbsp;</span></li><li><span style="text-align:unset">طفح جلدي، أو حكة، أو تقشّر، أو تقشير</span></li></ul><p dir="rtl"><strong>إذا حدثت لك هذه الأعراض، فتوقف عن تناول أونجليزا واتصل بمقدم الرعاية الصحية المتابع لك على الفور.<br />تحذيرات واحتياطات:</strong><br />أبلغ مقدم الرعاية الصحية إذا سبق لك أن عانيت أي اً من الأمور التالية</p><ul dir="rtl"><li>التهاب البنكرياس&nbsp;</li><li>الحصى في المرارة&nbsp;</li><li>تاريخ من الإدمان على الكحول</li><li>ارتفاع مستويات الدهون الثلاثية في الدم</li></ul><p dir="rtl">ليس من المعروف ما إذا كان وجود هذه المشاكل الطبية سيجعلك أكثر عرضة للإصابة بالتهاب البنكرياس عند تناول أونجليزا.<br />أوقف تناول أونجليزا واتصل بمقدم الرعاية الصحية على الفور إذا شعرت بألم شديد لا يتلاشى في منطقة المعدة (البطن). قد تشعر<br />بالألم يمتد من بطنك نحو ظهرك. وقد يحدث الألم مع قيء أو بدونه. قد تشكّل هذه الأمور أعراض اً لالتهاب البنكرياس.<br />قبل أن تتناول أونجليزا، أبلغ مقدم الرعاية الصحية:</p><ul dir="rtl"><li>إذا كنت تعاني مشاكل في الكلى.</li></ul><p dir="rtl"><strong>الأطفال والمراهقون</strong><br />لا يُوصى باستخدام أونجليزا للأطفال والمراهقين دون سن ١٨ عاماً. غير معروف ما إذا كان تناول أونجليزا آمن اً وفعالا للأطفال دون<br />سن ١٨ عاماً.<br /><strong>أبلغ مقدم الرعاية الصحية بكل الأدوية التي تتناولها،</strong> بما في ذلك الأدوية التي تتناولها بناءً على وصفة الطبيب، وتلك التي تتناولها<br />بدون وصفة طبيب، والفيتامينات، والمكمِّلات العشبية.<br />اعرف الأدوية التي تتناولها. احتفظ بقائمة تسجل فيها الأدوية التي تتناولها، واعرضها على مقدم الرعاية الصحية والصيدلي عند شراء<br />دواء جديد.</p><p dir="rtl">يمكن أن يؤثر أونجليزا على مفعول الأدوية الأخرى، كما يمكن أن تؤثر الأدوية الأخرى على مفعوله. اتصل بمقدم الرعاية الصحية إذا<br />كنت ستبدأ في تناول أنواع معينة من الأدوية أو تتوقف عن تناولها، مثل المضادات الحيوية أو الأدوية التي تعالج الفطريات أو فيروس</p><p dir="rtl">نقص المناعة البشرية/الإيدز&nbsp;،(HIV/AIDS)&nbsp;حيث إنه قد يلزم تغيير جرعة أونجليزا التي تتناولها.</p><p dir="rtl"><strong>الحمل والرضاعة</strong><br />قبل أن تتناول أونجليزا، أبلغ مقدم الرعاية الصحية:</p><ul dir="rtl"><li>إذا كنتِ سيدة حاملا أو تنوين الحمل. ليس معروف اً ما إذا كان أونجليزا سيسبب ضرر اً للجنين أم لا. إذا كنتِ حاملاً، فتحدثي مع&nbsp; مقدم الرعاية الصحية حول أفضل طريقة للتحكم في مستوى السكر في دمك خلال الحمل.</li><li>إذا كنتِ تُرضِعين طفلك طبيعي اً أو تخططين لذلك. قد ينتقل أونجليزا عبر حليبكِ إلى طفلكِ. تحدثي مع مقدم الرعاية الصحية حول أفضل طريقة لتغذية الطفل أثناء تناول أونجليزا.</li></ul><p dir="rtl"><strong>القيادة واستخدام الآلات</strong><br />إذا كنت تشعر بدوخة عند تناول أونجليزا، لا تقُد السيارة أو تستخدم أيّ أدوات أو آلات. بإمكان نقص سكر الدم أن يؤثر على قدرتك<br />على القيادة واستخدام الآلات أو العمل بقدم ثابتة، كما إنك عرضة لخطر نقص سكر الدم عند تناول هذا الدواء بمصاحبة أدوية من<br />المعروف أنها تسبب نقص سكر الدم مثل الأنسولين وسلفونيل يوريا.<br /><strong>يحتوي أونجليزا على اللاكتوز</strong><br />تحتوي الأقراص على لاكتوز (سكر الحليب). إذا أخبرك الطبيب أنك لا تحتمل بعض أنواع السكر، فاتصل بطبيبك قبل تناول هذا<br />الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>كيف يجب عليّ أن أتناول أونجليزا؟</strong></p><ul dir="rtl"><li>تناول أونجليزا عن طريق الفم مرة واحدة في اليوم وبدقة وفق اً لإرشادات مقدم الرعاية الصحية. لا تغيّر جرعتك بدون استشارة مقدم الرعاية الصحية أولاً.</li><li>بالإمكان تناول أونجليزا مع الطعام أو بدونه.&nbsp;</li><li>لا تقسم أقراص أونجليزا أو تقصّها.&nbsp;</li><li>أثناء الأوقات التي يعاني الجسم خلالها من الضغوط، مثل:&nbsp;</li><li>الحمى&nbsp;</li><li>الصدمات&nbsp;</li><li>العدوى&nbsp;</li><li>الجراحة&nbsp;</li></ul><p style="direction: rtl;">اتصل بمقدم الرعاية الصحية على الفور إذ إن احتياجاتك للدواء قد تتغير.</p><ul dir="rtl"><li>يجب على مقدم الرعاية الصحية أن يفحص دمك لقياس مدى عمل الكليتين قبل العلاج بواسطة أونجليزا وأثناءه. قد يكون عليك&nbsp;تناول جرعة أقل من أونجليزا إذا لم تكن كليتاك تعملان بشكل جيد.</li><li>اتبع تعليمات مقدم الرعاية الصحية فيما يتعلق بعلاج انخفاض السكر في دمك بشكل كبير (نقص سكر الدم). تحدث إلى مقدم&nbsp; الرعاية الصحية إذا كان انخفاض مستوى السكر في الدم يمثل مشكلة بالنسبة إليك.</li><li>تناول هذا الدواء دائم اً وبدقة وفق اً لتوجيهات الطبيب. استشر طبيبك أو الصيدلي إذا كانت تساورك أيّ شكوك.</li></ul><p dir="rtl"><strong>إذا تناولت جرعة من أونجليزا أكثر مما يجب</strong><br />إذا تناولت جرعة كبيرة للغاية من أونجليزا، فاتصل بمقدم الرعاية الصحية المتابع لك أو بأحد مراكز علاج السموم، أو توجه إلى غرفة<br />الطوارئ في أقرب مستشفى على الفور.<br /><strong>إذا كنت قد نسيت أن تتناول أونجليزا</strong><br />إذا نسيت تناول جرعة من أونجليزا، فتناولها بمجرد أن تتذكر. إذا كان وقت الجرعة التالية على وشك أن يحين، فلا تتناول الجرعة<br />التي نسيتها. وإنما تناول الجرعة التالية فقط في وقتها المعتاد. لا تتناول جرعتين في نفس الوقت إلا إذا طلب منك مقدم الرعاية الصحية<br />ذلك. تحدث مع مقدم الرعاية الصحية إذا كانت لديك أي أسئلة حول الجرعة الفائتة.<br /><strong>إذا توقفت عن تناول أونجليزا</strong><br />استمر في تناول أونجليزا حتى يخبرك الطبيب أن توقفه. يساعدك هذا الأمر على مواصلة التحكم في مستوى السكر في الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">شأنه شأن جميع الأدوية، قد يسبب هذا الدواء آثار اً جانبية على الرغم من أنها لا تصيب الجميع.</span></div><div style="direction: rtl;"><strong><span style="text-align:unset">ما أهم المعلومات التي يجب عليّ أن أعرفها بخصوص أونجليزا؟</span></strong></div><div style="direction: rtl;"><span style="text-align:unset"><strong>قد تحدث آثار جانبية خطيرة للأشخاص الذين يتناولون أونجليزا،</strong> بما في ذلك التهاب البنكرياس الذي قد يكون شديد اً ويؤدّي إلى</span></div><div style="direction: rtl;"><span style="text-align:unset">الموت.</span></div><div style="direction: rtl;"><span style="text-align:unset">قد يعرّضك بعض المشاكل الطبية أكثر من غيرها للإصابة بالتهاب البنكرياس.</span></div><div style="direction: rtl;"><strong><span style="text-align:unset">قد يتسبّب تناول أونجليزا في حدوث آثار جانبية خطيرة، بما في ذلك:</span></strong></div><div style="direction: rtl;">انظر إلى &quot;<strong>ما أهم المعلومات التي يجب أن أعرفها بخصوص أونجليزا؟&quot;&nbsp;</strong><br /><strong>ردود فعل حساسية (فرط الحساسية)، </strong>مثل:</div><ul dir="rtl"><li>تورم الوجه، والشفتين، والحلق، ومناطق أخرى على البشرة&nbsp;</li><li>صعوبة في البلع أو التنفس&nbsp;</li><li>مناطق حمراء، مرتفعة عن الجلد (شَرَىَ)&nbsp;</li><li>طفح جلدي، أو حكة، أو تقشّر، أو تقشير&nbsp;</li></ul><div style="direction: rtl;">إذا حدثت لك هذه الأعراض، فتوقف عن تناول أونجليزا واتصل بمقدم الرعاية الصحية المتابع لك على الفور.</div><div style="direction: rtl;">&nbsp;</div><ul dir="rtl"><li><strong>ألم في المفاصل.</strong> قد يصاب بعض الأشخاص الذين يتناولون أدوية تُسمى مثبطات&nbsp;،DPP-4،&nbsp;مثل أونجليزا، بألم في المفاصل يمكن&nbsp;أن يكون شديداً. اتصل بمقدم الرعاية الصحية إذا عانيت ألم اً شديد اً في المفاصل.</li></ul><p dir="rtl"><strong>تشمل آثار أونجليزا الجانبية الشائعة ما يلي:</strong></p><ul dir="rtl"><li>التهابات الجهاز التنفسي العلوي&nbsp;</li><li>التهابات المسالك البولية&nbsp;</li><li>الصداع&nbsp;</li></ul><p dir="rtl">قد يتفاقم <strong>انخفاض مستوى السكر في الدم (نقص سكر الدم)</strong> لدى الأشخاص الذين يتناولون أدوية أخرى لعلاج السكري، مثل أدوية<br />السلفونيل يوريا أو الأنسولين. أبلغ مقدم الرعاية الصحية المتابع لك إذا كنت تتناول أدوية أخرى لعلاج السكري. إذا كنت تعاني<br />أعراض انخفاض مستوى السكر في الدم، فيجب عليك أن تفحص مستوى السكر في دمك وأن تعالجه إذا كان منخفضاً، ثم عليك أن<br />تتصل بمقدم الرعاية الصحية المتابع لك. تشمل أعراض انخفاض مستوى السكر في الدم ما يلي:</p><ul dir="rtl"><li>الرجفة&nbsp;</li><li>التعرّق&nbsp;</li><li>سرعة ضربات القلب&nbsp;</li><li>التغيّر في الرؤية&nbsp;</li><li>الجوع&nbsp;</li><li>الصداع&nbsp;</li><li>تغيّرات المزاج&nbsp;</li></ul><p dir="rtl"><strong>قد يتفاقم التورم أو احتباس السوائل </strong>في يديك أو قدميك أو كاحليك (الوذمة المحيطية) لدى الأشخاص الذين يتناولون ثيازوليدينيديون<br />أيض اً لعلاج السكري. وإذا لم تكن تعرف ما إذا تتناول هذا النوع من الدواء، فاسأل مقدم الرعاية الصحية المتابع لك.<br /><strong>ليست هذه كل آثار أونجليزا الجانبية المحتملة.</strong></p><p dir="rtl"><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا شعرت بأي آثار جانبية، فتحدّث إلى طبيبك أو الصيدلي أو الممرضة. وهذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه<br />النشرة. كما يمكنك الإبلاغ عن هذه الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية، يمكنك تقديم مزيدٍ من<br />المعلومات عن سلامة هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">- احتفظ بهذا الدواء بعيد اً عن مرأى ومتناول الأطفال.</span></div><div style="direction: rtl;"><span style="text-align:unset">- لا يُحفظ في حرارة أعلى من ٣٠ درجة مئوية.</span></div><div style="direction: rtl;">- لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدوّن على الشريط وعلى العلبة الخارجية. يشير تاريخ انتهاء الصلاحية إلى<br />آخر يوم من الشهر المدوّن.<br />- لا تستخدم هذا الدواء إذا كانت العبوة تالفة أو تظهر عليها علامات تلاعب.<br />- لا ترمِ الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن إجراءات رمي الأدوية التي لم تعد تستعملها.<br />ستساعد هذه الإجراءات على حماية البيئة.</div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">- المادة الفعالة: ساكساجليبتين</span></div><div style="direction: rtl;"><span style="text-align:unset">- المواد غير الفعالة: مونوهيدرات اللاكتوز، سيلولوز بلوري مكروي، كروسكارميلوز الصوديوم، ستيارات المغنيسيوم. إضافة إلى ذلك، تحتوي الطبقة الرقيقة المغلِّفة على المواد غير الفعالة التالية: كحول البولي فينيل، غليكول بولي إيثيلين، ثاني أكسيد</span></div><div style="direction: rtl;"><span style="text-align:unset">التيتانيوم، التلك، أكسيدات حديد.</span></div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص ٢٫٥ ملغ مغلفة لونها أصفر باهت مائل إلى الأصفر الفاتح، وثنائية التحدّب، ومستديرة. تحمل على أحد جانبيها 
الرقم " ٢٫٥ " وعلى الجانب الآخر الرقم " ٤٢١٤ " مطبوعَين بالحبر الأزرق.
أقراص ٥ ملغ مغلفة وردية اللون، وثنائية التحدّب، ومستديرة. تحمل على أحد جانبيها الرقم " ٥" وعلى الجانب الآخر الرقم
٤٢١٥ " مطبوعَين بالحبر الأزرق.
١ في زجاجة. × تتوفر أقراص ٢٫٥ ملغ في عبوات أقراص مغلفة بأحجام ٣٠ 
تتوفر أقراص ٥ ملغ في عبوات أقراص مغلفة بأحجام ٣٠في زجاجة. × 
قد لا يتم تسويق جميع أحجام العبوات في بلدك.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل ترخيص التسويق والشركة المصنعة<br />حامل ترخيص التسويق:<br />(SITCO) الشركة السعودية للتجارة المحدودة<br />ص.ب. ٥١٣٢ ، الرياض ١١٤٢٢ ، المملكة العربية السعودية<br />الشركة المصنعة:<br />AstraZeneca Pharmaceuticals LP<br />4601 Highway 62 East<br />Mount Vernon, Indiana 47620, USA<br />AstraZeneca : الشركة المسو</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Onglyza 2.5 mg film-coated tablets
Onglyza 5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 2.5 mg saxagliptin (as hydrochloride).
Each tablet contains 5 mg saxagliptin (as hydrochloride).
Excipient(s) with known effect:
Each tablet contains 99 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Onglyza 2.5 mg tablets are pale yellow to light yellow, biconvex, round, film-coated tablets, with “2.5” printed on
one side and “4214” printed on the other side, in blue ink.
Onglyza 5 mg tablets are pink, biconvex, round, film-coated tablet, with “5” printed on one side and “4215”
printed on the other side, in blue ink.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Onglyza is indicated in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve<br />glycaemic control:<br />&bull; As monotherapy when metformin is inappropriate due to intolerance or contraindications<br />&bull; In combination with other medicinal products for the treatment of diabetes, including insulin, when these do not<br />provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />The recommended dosage of ONGLYZA is 2.5 mg or 5 mg once daily taken regardless of meals. ONGLYZA tablets must<br />not be split or cut.<br /><u>Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors</u><br />The dosage of ONGLYZA is 2.5 mg once daily when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5)<br />inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,<br />saquinavir, and telithromycin). (see section 4.4 and 4.5)<br /><u>Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</u><br />When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of<br />the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia [see 4.4 Special warnings and<br />precautions for use].<br /><br /><u>Special populations<br />Elderly (&ge; 65 years)</u><br />No dose adjustment is recommended based solely on age (see sections 5.1 and 5.2).<br /><u>Renal impairment</u><br />No dosage adjustment for ONGLYZA is recommended for patients with mild renal impairment (creatinine clearance<br />[CrCl] &gt;50 mL/min).<br />The dosage of ONGLYZA is 2.5 mg once daily (regardless of meals) for patients with moderate or severe renal<br />impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (creatinine clearance [CrCl] 50 mL/min) (see<br />section 5.2). ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients<br />undergoing peritoneal dialysis.<br />Because the dosage of ONGLYZA should be limited to 2.5 mg based upon renal function, assessment of renal function is<br />recommended prior to initiation of ONGLYZA and periodically thereafter. Renal function can be estimated from serum<br />creatinine using the Cockcroft-Gault formula or Modification of Diet in Renal Disease formula.<br /><u>Hepatic impairment</u><br />No dose adjustment is necessary for patients with mild or moderate hepatic impairment (see section 5.2).<br />Saxagliptin should be used with caution in patients with moderate hepatic impairment, and is not recommended for<br />use in patients with severe hepatic impairment (see section 4.4).<br />Paediatric population<br />Safety and effectiveness of ONGLYZA in pediatric patients under 18 years of age have not been established. Additionally,<br />studies characterizing the pharmacokinetics of ONGLYZA in pediatric patients have not been performed.<br /><u>Method of administration</u><br />The tablets can be taken with or without a meal at any time of the day. Tablets must not be split or cut.<br />If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the<br />same day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ONGLYZA is contraindicated in patients with a history of a serious hypersensitivity reaction to ONGLYZA, such as
anaphylaxis, angioedema, or exfoliative skin conditions [see 4.4 Special warnings and precautions for use and 4.8
Undesirable effects].
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u><br />ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be<br />effective in these settings.<br />ONGLYZA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of<br />pancreatitis are at an increased risk for the development of pancreatitis while using ONGLYZA.</p><p><u>Pancreatitis</u><br />There have been postmarketing reports of acute pancreatitis in patients taking ONGLYZA. After initiation of<br />ONGLYZA, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected,<br />ONGLYZA should promptly be discontinued and appropriate management should be initiated. It is unknown<br />whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using<br />ONGLYZA.<br /><u>Renal impairment</u><br />A single dosage adjustment is recommended in patients with moderate or severe renal impairment. Saxagliptin<br />is not recommended for use in patients with end-stage renal disease (ESRD) requiring haemodialysis.<br />Assessment of renal function is recommended prior to initiation of Onglyza, and, in keeping with routine care,<br />renal assessment should be done periodically thereafter (see sections 4.2 and 5.2).<br /><u>Hepatic impairment</u><br />Saxagliptin should be used with caution in patients with moderate hepatic impairment, and is not recommended<br />for use in patients with severe hepatic impairment (see section 4.2).<br />Use with medicinal products known to cause hypoglycaemia<br />When ONGLYZA was used in combination with a sulfonylurea or with insulin, medications known to cause<br />hypoglycemia, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a<br />sulfonylurea or with insulin [see 4.8 Undesirable effects]. Therefore, a lower dose of the insulin secretagogue or insulin<br />may be required to minimize the risk of hypoglycemia when used in combination with ONGLYZA [see 4.2 Posology<br />and method of administration].<br /><u>Hypersensitivity reactions</u><br />There have been postmarketing reports of serious hypersensitivity reactions in patients treated with ONGLYZA. These<br />reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the<br />first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose. If a serious<br />hypersensitivity reaction is suspected, discontinue ONGLYZA, assess for other potential causes for the event, and<br />institute alternative treatment for diabetes [see 4.8 Undesirable effects].<br />Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is<br />unknown whether such patients will be predisposed to angioedema with ONGLYZA.<br /><u>Severe and Disabling Arthralgia</u><br />There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP4 inhibitors. The time to<br />onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of<br />symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when<br />restarting the same drug or a different DPP4 inhibitor. Consider DPP4 inhibitors as a possible cause for severe joint pain<br />and discontinue drug if appropriate.</p><p><u>Macrovascular Outcomes</u><br />There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA<br />or any other antidiabetic drug.<br /><u>Use with potent CYP 3A4 inducers</u><br />Ketoconazole significantly increased saxagliptin exposure. Similar significant increases in plasma concentrations of<br />saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir,<br />itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). The dose of ONGLYZA should be<br />limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (see section 4.5)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In Vitro Assessment of Drug Interactions</em><br />The metabolism of saxagliptin is primarily mediated by CYP3A4/5.<br />In in vitro studies, saxagliptin and its active metabolite did not inhibit CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or<br />3A4, or induce CYP1A2, 2B6, 2C9, or 3A4. Therefore, saxagliptin is not expected to alter the metabolic clearance of<br />coadministered drugs that are metabolized by these enzymes. Saxagliptin is a P-glycoprotein (P-gp) substrate but is not<br />a significant inhibitor or inducer of P-gp.</p><p><strong><em>In Vivo Assessment of Drug Interactions</em></strong></p><p>&nbsp;</p><p><strong>Table 1: Effect of Coadministered Drugs on Systemic Exposures of Saxagliptin and its Active Metabolite, 5- hydroxy Saxagliptin</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Coadministered</strong></p><p><strong>Drug</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>D</strong><strong>osage of</strong></p><p><strong>Coadministered Drug*</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Dosage of</strong></p><p><strong>Saxagliptin*</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Geometric Mean Ratio</strong></p><p><strong>(ratio with/without coadministered drug) No Effect = 1.00</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>A</strong><strong>U</strong><strong>C</strong><strong>&dagger;</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>m</strong><strong>ax</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>No dosing adjustments required for the following:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>1000 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>0.98</p><p>0.99</p></td><td style="vertical-align:top"><p>0.79</p><p>0.88</p></td></tr><tr><td style="vertical-align:top"><p>Glyburide</p></td><td style="vertical-align:top"><p>5 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>0.98</p><p>ND</p></td><td style="vertical-align:top"><p>1.08</p><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>Pioglitazone&Dagger;</p></td><td style="vertical-align:top"><p>45 mg QD for 10 days</p></td><td style="vertical-align:top"><p>10 mg QD</p><p>for 5 days</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>1.11</p><p>ND</p></td><td style="vertical-align:top"><p>1.11</p><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin</p></td><td style="vertical-align:top"><p>0.25 mg q6h first day followed by q12h second day followed by QD for 5 days</p></td><td style="vertical-align:top"><p>10 mg QD</p><p>for 7 days</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>1.05</p><p>1.06</p></td><td style="vertical-align:top"><p>0.99</p><p>1.02</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin</p></td><td style="vertical-align:top"><p>40 mg QD for 8 days</p></td><td style="vertical-align:top"><p>10 mg QD</p><p>for 4 days</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>1.12</p><p>1.02</p></td><td style="vertical-align:top"><p>1.21</p><p>1.08</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem</p></td><td style="vertical-align:top"><p>360 mg LA QD for 9 days</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>2.09</p><p>0.66</p></td><td style="vertical-align:top"><p>1.63</p><p>0.57</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin&sect;</p></td><td style="vertical-align:top"><p>600 mg QD for 6 days</p></td><td style="vertical-align:top"><p>5 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>0.24</p><p>1.03</p></td><td style="vertical-align:top"><p>0.47</p><p>1.39</p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole</p></td><td style="vertical-align:top"><p>40 mg QD for 5 days</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>1.13</p><p>ND</p></td><td style="vertical-align:top"><p>0.98</p><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>Aluminum hydroxide + magnesium hydroxide + simethicone</p></td><td style="vertical-align:top"><p>aluminum hydroxide:</p><p>2400 mg magnesium hydroxide:</p><p>2400 mg simethicone: 240 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>0.97</p><p>ND</p></td><td style="vertical-align:top"><p>0.74</p><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>Famotidine</p></td><td style="vertical-align:top"><p>40 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>1.03</p><p>ND</p></td><td style="vertical-align:top"><p>1.14</p><p>ND</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Limit ONGLYZA dose to 2.5 mg once daily when coadministered with strong CYP3A4/5 inhibitors [<em>see 4.5</em></strong></p><p><strong><em>Interaction with other medicinal products and other forms of interaction </em></strong><strong>a</strong><strong>nd <em>4.2 Posology and method of administration</em>]:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p></td><td style="vertical-align:top"><p>200 mg BID for 9 days</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>2.45</p><p>0.12</p></td><td style="vertical-align:top"><p>1.62</p><p>0.05</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p></td><td style="vertical-align:top"><p>200 mg BID for 7 days</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>saxagliptin</p><p>5-hydroxy saxagliptin</p></td><td style="vertical-align:top"><p>3.67</p><p>ND</p></td><td style="vertical-align:top"><p>2.44</p><p>ND</p></td></tr></tbody></table><p>* Single dose unless otherwise noted</p><p>&dagger;&nbsp;&nbsp; &nbsp;AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses</p><p>&Dagger;&nbsp;&nbsp; &nbsp;Results exclude one subject</p><p>&sect;&nbsp;&nbsp; &nbsp;The plasma dipeptidyl peptidase-4 (DPP4) activity inhibition over a 24-hour dose interval was not affected by rifampin.</p><p>ND=not determined; QD=once daily; q6h=every 6 hours; q12h=every 12 hours; BID=twice daily; LA=long acting</p><p>&nbsp;</p><p><strong>Table 2: Effect of Saxagliptin on Systemic Exposures of Coadministered Drugs</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Coadministered</strong></p><p><strong>Drug</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Dosag</strong><strong>e of</strong></p><p><strong>Coadministered Drug*</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>D</strong><strong>osage of</strong></p><p><strong>Saxagliptin*</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>G</strong><strong>eometric Mean Ratio (ratio with/without saxagliptin) No Effect = 1.00</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>AU</strong><strong>C</strong><strong>&dagger;</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>max</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>No dosing adjustments required for the following:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>1000 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>metformin</p></td><td style="vertical-align:top"><p>1.20</p></td><td style="vertical-align:top"><p>1.09</p></td></tr><tr><td style="vertical-align:top"><p>Glyburide</p></td><td style="vertical-align:top"><p>5 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>glyburide</p></td><td style="vertical-align:top"><p>1.06</p></td><td style="vertical-align:top"><p>1.16</p></td></tr><tr><td style="vertical-align:top"><p>Pioglitazone&Dagger;</p></td><td style="vertical-align:top"><p>45 mg QD for 10 days</p></td><td style="vertical-align:top"><p>10 mg QD</p><p>for 5 days</p></td><td style="vertical-align:top"><p>pioglitazone</p><p>hydroxy-pioglitazone</p></td><td style="vertical-align:top"><p>1.08</p><p>ND</p></td><td style="vertical-align:top"><p>1.14</p><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin</p></td><td style="vertical-align:top"><p>0.25 mg q6h first day followed by q12h second day followed by QD for 5 days</p></td><td style="vertical-align:top"><p>10 mg QD</p><p>for 7 days</p></td><td style="vertical-align:top"><p>digoxin</p></td><td style="vertical-align:top"><p>1.06</p></td><td style="vertical-align:top"><p>1.09</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin</p></td><td style="vertical-align:top"><p>40 mg QD for 8 days</p></td><td style="vertical-align:top"><p>10 mg QD</p><p>for 4 days</p></td><td style="vertical-align:top"><p>simvastatin simvastatin acid</p></td><td style="vertical-align:top"><p>1.04</p><p>1.16</p></td><td style="vertical-align:top"><p>0.88</p><p>1.00</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem</p></td><td style="vertical-align:top"><p>360 mg LA QD for 9 days</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>diltiazem</p></td><td style="vertical-align:top"><p>1.10</p></td><td style="vertical-align:top"><p>1.16</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p></td><td style="vertical-align:top"><p>200 mg BID for 9 days</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>ketoconazole</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>0.84</p></td></tr><tr><td style="vertical-align:top"><p>Ethinyl estradiol and Norgestimate</p></td><td style="vertical-align:top"><p>ethinyl estradiol 0.035 mg and norgestimate 0.250 mg</p><p>for 21 days</p></td><td style="vertical-align:top"><p>5 mg QD for</p><p>21 days</p></td><td style="vertical-align:top"><p>ethinyl estradiol norelgestromin norgestrel</p></td><td style="vertical-align:top"><p>1.07</p><p>1.10</p><p>1.13</p></td><td style="vertical-align:top"><p>0.98</p><p>1.09</p><p>1.17</p></td></tr></tbody></table><p>* &nbsp;&nbsp;&nbsp; Single dose unless otherwise noted</p><p>&dagger; &nbsp;&nbsp;&nbsp; AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses</p><p>&Dagger; &nbsp;&nbsp;&nbsp; Results include all subjects</p><p>ND=not determined; QD=once daily; q6h=every 6 hours; q12h=every 12 hours; BID=twice daily; LA=long acting</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>P</u><u>regnancy</u></p><p>There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ONGLYZA, like other antidiabetic medications, should be used during pregnancy</p><p>only if clearly needed.</p><p>&nbsp;</p><p>Saxagliptin was not teratogenic at any dose tested when administered to pregnant rats and rabbits during periods of organogenesis. Incomplete ossification of the pelvis, a form of developmental delay, occurred in rats at a dose of</p><p>240 mg/kg, or approximately 1503 and 66 times human exposure to saxagliptin and the active metabolite,</p><p>respectively, at the maximum recommended human dose (MRHD) of 5 mg. Maternal toxicity and reduced fetal body weights were observed at &nbsp;7986 &nbsp;and &nbsp;328 &nbsp;times &nbsp;the &nbsp;human &nbsp;exposure &nbsp;at &nbsp;the &nbsp;MRHD &nbsp;for &nbsp;saxagliptin &nbsp;and &nbsp;the &nbsp;active</p><p>metabolite, respectively. Minor skeletal variations in rabbits occurred at a maternally toxic dose of 200 mg/kg, or approximately 1432 and 992 times the MRHD.</p><p>&nbsp;</p><p>Coadministration of saxagliptin and metformin, to pregnant rats and rabbits during the period of organogenesis, was neither embryolethal nor teratogenic in either species when tested at doses yielding systemic exposures (AUC) up to</p><p>100 and 10 times the MRHD (saxagliptin 5 mg and metformin 2000 mg), respectively, in rats; and 249 and 1.1 times</p><p>the MRHDs in rabbits. In rats, minor developmental toxicity was limited to an increased incidence of wavy ribs; associated maternal toxicity was limited to weight decrements of 11% to 17% over the course of the study, and related reductions in maternal food consumption. In rabbits, coadministration was poorly tolerated in a subset of mothers (12 of 30), resulting in death, moribundity, or abortion. However, among surviving mothers with evaluable litters, maternal toxicity was limited to marginal reductions in body weight over the course of gestation days 21 to 29; and associated developmental toxicity in these litters was limited to fetal body weight decrements of 7%, and a low incidence of delayed ossification of the fetal hyoid.</p><p>&nbsp;</p><p>Saxagliptin administered to female rats from gestation day 6 to lactation day 20 resulted in decreased body weights in male and female offspring only at maternally toxic doses (exposures &ge;1629 &nbsp;and &nbsp;53 &nbsp;times &nbsp;saxagliptin &nbsp;and &nbsp;its &nbsp;active</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 margin-left:150.9pt;margin-top:775.4pt;width:.7pt;height:2.95pt;z-index:-3852;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 coordorigin="3018,15508" coordsize="14,59">
 <v:shape id="_x0000_s1027" style='position:absolute;left:3018;top:15508;
  width:14;height:59' coordorigin="3018,15508" coordsize="14,59" path="m3032,15508r-14,14l3018,15566r14,l3032,15508e"
  fillcolor="gray" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="2" height="5" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1028" style='position:absolute;margin-left:231.3pt;margin-top:775.4pt;
 width:.7pt;height:2.95pt;z-index:-3851;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="4626,15508" coordsize="14,59">
 <v:shape id="_x0000_s1029" style='position:absolute;left:4626;top:15508;
  width:14;height:59' coordorigin="4626,15508" coordsize="14,59" path="m4640,15508r-14,14l4626,15566r14,l4640,15508e"
  fillcolor="gray" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="1" height="5" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1030" style='position:absolute;margin-left:301.45pt;margin-top:775.4pt;
 width:.7pt;height:2.95pt;z-index:-3850;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="6029,15508" coordsize="14,59">
 <v:shape id="_x0000_s1031" style='position:absolute;left:6029;top:15508;
  width:14;height:59' coordorigin="6029,15508" coordsize="14,59" path="m6043,15508r-14,14l6029,15566r14,l6043,15508e"
  fillcolor="gray" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="2" height="5" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1032" style='position:absolute;margin-left:386.9pt;margin-top:775.4pt;
 width:.7pt;height:2.95pt;z-index:-3849;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="7738,15508" coordsize="14,59">
 <v:shape id="_x0000_s1033" style='position:absolute;left:7738;top:15508;
  width:14;height:59' coordorigin="7738,15508" coordsize="14,59" path="m7752,15508r-14,14l7738,15566r14,l7752,15508e"
  fillcolor="gray" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="2" height="5" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1034" style='position:absolute;margin-left:469.4pt;margin-top:775.4pt;
 width:.7pt;height:2.95pt;z-index:-3848;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="9388,15508" coordsize="14,59">
 <v:shape id="_x0000_s1035" style='position:absolute;left:9388;top:15508;
  width:14;height:59' coordorigin="9388,15508" coordsize="14,59" path="m9402,15508r-14,14l9388,15566r14,l9402,15508e"
  fillcolor="gray" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="2" height="5" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1036" style='position:absolute;margin-left:549.7pt;margin-top:775.4pt;
 width:.8pt;height:2.95pt;z-index:-3847;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="10994,15508" coordsize="16,59">
 <v:shape id="_x0000_s1037" style='position:absolute;left:10994;top:15508;
  width:16;height:59' coordorigin="10994,15508" coordsize="16,59" path="m11010,15508r-16,14l10994,15566r16,l11010,15508e"
  fillcolor="gray" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="1" height="5" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>metabolite &nbsp;at &nbsp;the &nbsp;MRHD). &nbsp;No &nbsp;functional &nbsp;or behavioral toxicity was observed in offspring of rats administered saxagliptin at any dose. Saxagliptin crosses the &nbsp;placenta into the fetus following dosing in pregnant rats.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Saxagliptin is secreted in the milk of lactating rats at approximately a 1:1 ratio with plasma drug concentrations. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should</p><p>be exercised when ONGLYZA is administered to a nursing woman.</p><p>&nbsp;</p><p><u>F</u><u>e</u><u>r</u><u>t</u><u>i</u><u>l</u><u>i</u><u>t</u><u>y</u></p><p>&nbsp;</p><p>The effect of saxagliptin on fertility in humans has not been studied. Effects on fertility were observed in male and female rats at high doses producing overt signs of toxicity (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Onglyza may have a negligible influence on the ability to drive and use machines.</p><p>When driving or using machines, it should be taken into account that dizziness has been reported in studies with saxagliptin. In addition, patients should be alerted to the risk of hypoglycaemia when Onglyza is used in combination</p><p>with other antidiabetic medicinal products known to cause hypoglycaemia (e.g. insulin, sulphonylureas).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>S</em><em>ummary of the safety profile</em></p><p>&nbsp;</p><p>The most commonly reported adverse reactions in placebo-controlled trials reported in &ge; 5% of patients treated with Onglyza 5 mg and more commonly &nbsp;than in patients treated with placebo are upper respiratory &nbsp;tract infection (7.7%), urinary tract infection (6.8%) and headache (6.5%).</p><p>&nbsp;</p><p>There were 4,148 patients with type 2 diabetes, including 3,021 patients treated with Onglyza, randomised in six double- blind, controlled clinical safety and efficacy studies conducted to evaluate the effects of saxagliptin on glycaemic control. In randomised, controlled, double-blind clinical trials (including developmental and postmarketing experience), over 17,000 patients with type 2 diabetes have been treated with Onglyza.</p><p>&nbsp;</p><p>In a pooled analysis of 1,681 patients with type 2 diabetes including 882 patients treated with Onglyza 5 mg, randomised in five double-blind, placebo-controlled clinical safety and efficacy studies conducted to evaluate the effects of saxagliptin on glycaemic control, the overall incidence of adverse events in patients treated with saxagliptin 5 mg was similar to placebo. Discontinuation of therapy due to adverse events was higher in patients who received saxagliptin 5 mg as compared to placebo (3.3% as compared to 1.8%).</p><p>&nbsp;</p><p><u>T</u><u>abu</u><u>l</u><u>a</u><u>te</u><u>d list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported in &ge; 5% of patients treated with saxagliptin 5 mg and more commonly than in patients treated with placebo or that were reported in &ge; 2% of patients treated with saxagliptin 5 mg and &ge;1 % more frequently compared to placebo from the pooled analysis of five studies of glycaemic control, plus an additional active-controlled study of initial combination with metformin are shown in Table 3.</p><p>&nbsp;</p><p>The adverse reactions are listed by system organ class and absolute frequency. Frequencies are defined as very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to 1/100), rare (&ge; 1/10,000 to 1/1,000), or very rare (&lt; 1/10,000), or not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>T</strong><strong>a</strong><strong>b</strong><strong>l</strong><strong>e 3 Frequency of adverse reactions by system organ class from clinical trials and postmarketing experience</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p><strong>Adverse reaction</strong></p></td><td colspan="5" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Frequency of adverse reactions by treatment regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Saxagliptin monotherapy</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Saxagliptin with</strong></p><p><strong>me</strong><strong>tformin1</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Saxagliptin with a sulphonylurea (glibenclamide)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>S</strong><strong>axagliptin with a thiazolidinedione</strong></p></td><td style="vertical-align:top"><p><strong>Saxagliptin as add-on to metformin plus a &nbsp;sulphonylurea</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>i &nbsp;f &nbsp;&nbsp;&nbsp;&nbsp; i</p><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hyper- sensitivity</p><p>reactions&dagger;&Dagger;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic</p><p>reactions &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; including anaphylactic shock&dagger;&Dagger;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyslipidaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestina </strong><strong>l disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain&dagger;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea4</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea&dagger;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis&dagger;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Constipation&dagger;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash&dagger;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis&dagger;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Pruritus&dagger;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria&dagger;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema&dagger;&Dagger;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculo-skeletal</strong></p><p><strong>and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive </strong><strong>sys</strong><strong>t</strong><strong>e</strong><strong>m and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>G</strong><strong>eneral disorders and</strong></p><p><strong>administration </strong><strong>site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>1Includes saxagliptin in add-on to metformin and initial combination with metformin</p><p>2Only in the initial combination therapy</p><p>3There was no statistically significant difference compared to placebo. The incidence of confirmed hypoglycaemia was uncommon for Onglyza 5 mg (0.8%) and placebo (0.7%)</p><p>4 The incidence of diarrhoea was 4.1% (36/882) in the saxagliptin 5 mg group and 6.1% (49/799) in the placebo group.</p><p>5As initial combination with metformin, myalgia is reported as uncommon</p><p>&dagger;Adverse reactions were identified through postmarketing surveillance</p><p>&Dagger;See sections 4.3 and 4.4</p><p>*Also reported during postmarketing surveillance (see section 4.4).</p><p>&nbsp;</p><p><strong>Clinical Trials Experience</strong></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p><strong>Adverse Reactions with Monotherapy and with Add-On Combination Therapy</strong></p><p>In two placebo-controlled monotherapy trials of 24-weeks duration, patients were treated with ONGLYZA 2.5 mg daily, ONGLYZA 5 mg daily, and placebo. Three 24-week, placebo-controlled, add-on combination therapy trials were also</p><p>conducted: one with metformin, one with a thiazolidinedione (pioglitazone or rosiglitazone), and one with glyburide. In these three trials, patients were randomized to add-on therapy with ONGLYZA 2.5 mg daily, ONGLYZA 5 mg daily, or</p><p>placebo. A saxagliptin 10 mg treatment arm was included in one of the monotherapy trials and in the add-on combination trial with metformin. The 10 mg dosage is not an approved dosage.</p><p>In a prespecified pooled analysis of the 24-week data (regardless of glycemic rescue) from the two monotherapy trials, the add-on to metformin trial, the add-on to thiazolidinedione (TZD) trial, and the add-on to glyburide trial, the overall</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>incidence of adverse events in patients treated with ONGLYZA 2.5 mg and ONGLYZA 5 mg was similar to placebo (72%</p><p>and 72.2% versus 70.6%, respectively). Discontinuation of therapy due to adverse events occurred in 2.2%, 3.3%, and</p><p>1.8% of patients receiving ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively. The most common adverse events (reported in at least 2 patients treated with ONGLYZA 2.5 mg or at least 2 patients treated with ONGLYZA 5 mg)</p><p>associated with premature discontinuation of therapy included lymphopenia (0.1% and 0.5% versus 0%, respectively), rash</p><p>(0.2% and 0.3% versus 0.3%), blood creatinine increased (0.3% and 0% versus 0%), and blood creatine phosphokinase increased (0.1% and 0.2% versus 0%). The adverse reactions in this pooled analysis reported (regardless of investigator</p><p>assessment of causality) in &ge;5% of patients treated with ONGLYZA 5 mg, and more commonly than in patients treated with placebo are shown in Table 4.</p><p>Table 4: Adverse Reactions in Placebo-Controlled Trials* Reported in &ge;5% of Patients Treated with ONGLYZA 5 mg and</p><p>More Commonly than in Patients Treated with Placebo</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>ONGLYZA 5 mg</strong></p><p><strong>N=882</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Placebo</strong></p><p><strong>N</strong><strong>=799</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>68 (7.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>61 (7.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>60 (6.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>49 (6.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>57 (6.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>47 (5.9)</p></td></tr></tbody></table><p>* &nbsp;The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of</p><p>the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue).</p><p>&nbsp;</p><p>In patients treated with ONGLYZA 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate 5% and more commonly than in patients treated with placebo.</p><p>In this pooled analysis, adverse reactions that were reported in 2% of patients treated with ONGLYZA 2.5 mg or</p><p>ONGLYZA 5 mg and 1% more frequently compared to placebo included: sinusitis (2.9% and 2.6% versus 1.6%, respectively), abdominal pain (2.4% and 1.7% versus 0.5%), gastroenteritis (1.9% and 2.3% versus 0.9%), and vomiting</p><p>(2.2% and 2.3% versus 1.3%).</p><p>In the add-on to TZD trial, the incidence of peripheral edema was higher for ONGLYZA 5 mg versus placebo (8.1% and</p><p>4.3%, respectively). The incidence of peripheral edema for ONGLYZA 2.5 mg was 3.1%. None of the reported adverse reactions of peripheral edema resulted in study drug discontinuation. Rates of peripheral edema for ONGLYZA 2.5 mg and</p><p>ONGLYZA 5 mg versus placebo were 3.6% and 2% versus 3% given as monotherapy, 2.1% and 2.1% versus 2.2% given as add-on therapy to metformin, and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.</p><p>The incidence rate of fractures was 1.0 and 0.6 per 100 patient-years, respectively, for ONGLYZA (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo. The 10 mg dosage is not an approved dosage. The incidence rate of fracture events in</p><p>patients who received ONGLYZA did not increase over time. Causality has not been established and nonclinical studies have not demonstrated adverse effects of ONGLYZA on bone.</p><p>An event of thrombocytopenia, consistent with a diagnosis of idiopathic thrombocytopenic purpura, was observed in the clinical program. The relationship of this event to ONGLYZA is not known.</p><p>&nbsp;</p><p><strong>Adverse Reactions in Patients with Renal Impairment</strong></p><p>ONGLYZA 2.5 mg was compared to placebo in a 12-week trial in 170 patients with type 2 diabetes and moderate or severe renal impairment or end-stage renal disease (ESRD). The incidence of adverse events, including serious adverse</p><p>events and discontinuations due to adverse events, was similar between ONGLYZA and placebo.</p><p>&nbsp;</p><p><strong>Adverse Reactions with Concomitant Use with Insulin</strong></p><p>In the add-on to insulin trial the incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between ONGLYZA and placebo, except for confirmed hypoglycemia [<em>see 4.8 Undesirable</em></p><p><em>effects</em>].</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>A</strong><strong>dverse Reactions with Concomitant Use with Metformin in Treatment-Naive Patients with Type 2 Diabetes </strong>Table 5 shows the adverse reactions reported (regardless of investigator assessment of causality) in &ge;5% of patients participating in an additional 24-week, active-controlled trial of coadministered ONGLYZA and metformin in treatment-naive patients</p><p>&nbsp;</p><p><strong>Table 5: Initial Therapy with Combination of ONGLYZA and Metformin in Treatment-Naive Patients: Adverse Reactions Reported in &ge;5% of Patients Treated with Combination Therapy of ONGLYZA 5 mg Plus Metformin (and More Commonly than in Patients Treated with Metformin Alone)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>N</strong><strong>umber (%) of Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>ONGLYZA 5 mg + Metformin* N=320</strong></p></td><td style="vertical-align:top"><p><strong>Metformin* N=328</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>24 (7.5)</p></td><td style="vertical-align:top"><p>17 (5.2)</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>22 (6.9)</p></td><td style="vertical-align:top"><p>13 (4.0)</p></td></tr></tbody></table><p><strong>* &nbsp;</strong>Metformin was initiated at a starting dose of 500 mg daily and titrated up to a maximum of 2000 mg daily.</p><p>&nbsp;</p><p><strong>Hypoglycemia</strong></p><p>Adverse reactions of hypoglycemia were based on all reports of hypoglycemia. A concurrent glucose measurement was not required or was normal in some patients. Therefore, it is not possible to conclusively determine that all these reports</p><p>reflect true hypoglycemia.</p><p>In the add-on to glyburide study, the overall incidence of reported hypoglycemia was higher for ONGLYZA 2.5 mg and</p><p>ONGLYZA 5 mg (13.3% and 14.6%) versus placebo (10.1%). The incidence of confirmed hypoglycemia in this study, defined as symptoms of hypoglycemia accompanied by a fingerstick glucose value of &le;50 mg/dL, was 2.4% and 0.8%</p><p>for ONGLYZA 2.5 mg and ONGLYZA 5 mg and 0.7% for placebo [<em>see 4.4 Special warnings and precautions for use</em>].</p><p>The incidence of reported hypoglycemia for ONGLYZA 2.5 mg and ONGLYZA 5 mg versus placebo given as monotherapy was 4% and 5.6% versus 4.1%, respectively, 7.8% and 5.8% versus 5% given as add-on therapy to</p><p>metformin, and 4.1% and 2.7% versus 3.8% given as add-on therapy to TZD. The incidence of reported hypoglycemia was 3.4% in treatment-naive patients given ONGLYZA 5 mg plus metformin and 4% in patients given metformin</p><p>alone.</p><p>In the active-controlled trial comparing add-on therapy with ONGLYZA 5 mg to glipizide in patients inadequately controlled on metformin alone, the incidence of reported hypoglycemia was 3% (19 events in 13 patients) with</p><p>ONGLYZA 5 mg versus 36.3% (750 events in 156 patients) with glipizide. Confirmed symptomatic hypoglycemia</p><p>(accompanying fingerstick blood glucose &le;50 mg/dL) was reported in none of the ONGLYZA-treated patients and in 35 glipizide-treated patients (8.1%) (p&lt;0.0001).</p><p>During 12 weeks of treatment in patients with moderate or severe renal impairment or ESRD, the overall incidence of reported hypoglycemia was 20% among patients treated with ONGLYZA 2.5 mg and 22% among patients treated with</p><p>placebo. Four ONGLYZA-treated patients (4.7%) and three placebo-treated patients (3.5%) reported at least one episode of confirmed symptomatic hypoglycemia (accompanying fingerstick glucose &le;50 mg/dL).</p><p>In the add-on to insulin trial, the overall incidence of reported hypoglycemia was 18.4% for ONGLYZA 5 mg and</p><p>19.9% for placebo. However, the incidence of confirmed symptomatic hypoglycemia (accompanying fingerstick blood glucose 50 mg/dL) was higher with ONGLYZA 5 mg (5.3%) versus placebo (3.3%).</p><p>In the add-on to metformin plus sulfonylurea trial, the overall incidence of reported hypoglycemia was 10.1% for</p><p>ONGLYZA 5 mg and 6.3% for placebo. Confirmed hypoglycemia was reported in 1.6% of the ONGLYZA-treated patients and in none of the placebo-treated patients [<em>see 4.4 Special warnings and precautions for use</em>].</p><p>&nbsp;</p><p><strong>Hypersensitivity Reactions</strong></p><p>&nbsp;</p><p>Hypersensitivity-related events, such as urticaria and facial edema in the 5-study pooled analysis up to Week 24 were reported in 1.5%, 1.5%, and 0.4% of patients who received ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively. None of these events in patients who received ONGLYZA required hospitalization or were reported as life-threatening by the investigators. One ONGLYZA-treated patient in this pooled analysis discontinued due to generalized urticaria and facial edema.</p><p>&nbsp;</p><p><strong>Infections</strong></p><p>In the unblinded, controlled, clinical trial database for ONGLYZA to date, there have been 6 (0.12%) reports of</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>tuberculosis among the 4959 ONGLYZA-treated patients (1.1 per 1000 patient-years) compared to no reports of tuberculosis among the 2868 comparator-treated patients. Two of these six cases were confirmed with laboratory testing. The remaining cases had limited information or had presumptive diagnoses of tuberculosis. None of the six cases occurred in the United States or in Western Europe. One case occurred in Canada in a patient originally from Indonesia who had recently visited Indonesia. The duration of treatment with ONGLYZA until report of tuberculosis ranged from 144 to 929 days. Post-treatment lymphocyte counts were consistently within the reference range for four cases. One patient had lymphopenia prior to initiation of ONGLYZA that remained stable throughout ONGLYZA treatment. The final patient had an isolated lymphocyte count below normal approximately four months prior to the report of tuberculosis. There have been no spontaneous reports of tuberculosis associated with ONGLYZA use. Causality has not been estimated and there are too few cases to date to determine whether tuberculosis is related to ONGLYZA use.</p><p>There has been one case of a potential opportunistic infection in the unblinded, controlled clinical trial database to date in an ONGLYZA-treated patient who developed suspected foodborne fatal salmonella sepsis after approximately 600</p><p>days of ONGLYZA therapy. There have been no spontaneous reports of opportunistic infections associated with</p><p>ONGLYZA use.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>V</strong><strong>i</strong><strong>t</strong><strong>al Signs</strong></p><p>&nbsp;</p><p>No clinically meaningful changes in vital signs have been observed in patients treated with ONGLYZA.</p><p>&nbsp;</p><p><strong>Laboratory Tests</strong></p><p><strong><em>Absolute Lymphocyte Counts</em></strong></p><p>&nbsp;</p><p>There was a dose-related mean decrease in absolute lymphocyte count observed with ONGLYZA. From a baseline mean absolute lymphocyte count of approximately 2200 cells/microL, mean decreases of approximately 100 and 120 cells/microL with ONGLYZA 5 mg and 10 mg, respectively, relative to placebo were observed at 24 weeks in a pooled analysis of five placebo-controlled clinical studies. Similar effects were observed when ONGLYZA 5 mg was given in initial combination with metformin compared to metformin alone. There was no difference observed for ONGLYZA 2.5 mg relative to placebo. The proportion of patients who were reported to have a lymphocyte count &le;750 cells/microL</p><p>was 0.5%, 1.5%, 1.4%, and 0.4% in the ONGLYZA 2.5 mg, 5 mg, 10 mg, and placebo groups, respectively. In most patients, recurrence was not observed with repeated exposure to ONGLYZA although some patients had recurrent</p><p>decreases upon rechallenge that led to discontinuation of ONGLYZA. The decreases in lymphocyte count were not</p><p>associated with clinically relevant adverse reactions. The 10 mg dosage is not an approved dosage.</p><p>&nbsp;</p><p>The clinical significance of this decrease in lymphocyte count relative to placebo is not known. When clinically indicated, such as in settings of unusual or prolonged infection, lymphocyte count should be measured. The effect of ONGLYZA on lymphocyte counts in patients with lymphocyte abnormalities (e.g., human immunodeficiency virus) is unknown.</p><p>&nbsp;</p><p><strong><em>Postmarketing Experience</em></strong></p><p>&nbsp;</p><p>Additional adverse reactions have been identified during postapproval use of ONGLYZA. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp; Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions [<em>see </em>4<em>.3 Contraindications </em>and <em>4.4 Special warnings and precautions for use</em>].</p><p> Acute pancreatitis [<em>see </em><em>4</em><em>.4 Special warnings and precautions for use</em>].</p><p> Severe and disabling arthralgia [<em>see </em><em>4.</em><em>4 Special warnings and precautions for use</em>].</p><p>&nbsp;</p><p><strong><em>Paediatric Population</em></strong></p><p>Safety and effectiveness of ONGLYZA in pediatric patients under 18 years of age have not been established. Additionally, studies characterizing the pharmacokinetics of ONGLYZA in pediatric patients have not been performed.</p><p>&nbsp;</p><p><strong><em>G</em></strong><strong><em>eriatric Population</em></strong></p><p>In the six, double-blind, controlled clinical safety and efficacy trials of ONGLYZA, 634 (15.3%) of the 4148 randomized patients were 65 years and over, and 59 (1.4%) patients were 75 years and over. No overall differences in safety or effectiveness were observed between patients 65 years old and the younger patients. While this clinical experience has not identified differences in responses between the elderly and younger patients, greater sensitivity of</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>some older individuals cannot be ruled out.</p><p>Saxagliptin and its active metabolite are eliminated in part by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function (<em>see </em>section</p><p><em>4</em><em>.</em><em>2 and &nbsp;5.2)</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a controlled clinical trial, once-daily, orally-administered ONGLYZA in healthy subjects at doses up to 400 mg daily for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on QTc interval or heart rate.</p><p>In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient&rsquo;s clinical status. Saxagliptin and its active metabolite are removed by hemodialysis (23% of dose over 4 hours).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:</p><p>Drugs used in diabetes. Dipeptidyl peptidase 4 (DPP4) inhibitors, ATC code: A10BH03</p><p><u>Mechanism of action</u></p><p>Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These</p><p>hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the</p><p>DPP4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to</p><p>GLP-1 is preserved. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones,</p><p>thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.</p><p>&nbsp;</p><p><u>P</u><u>harmacodynamic effects</u></p><p>&nbsp;</p><p>In patients with type 2 diabetes mellitus, administration of ONGLYZA inhibits DPP4 enzyme activity for a 24-hour period. After an oral glucose load or a meal, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased glucose-dependent insulin secretion from pancreatic beta cells. The rise in insulin and decrease in glucagon were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.</p><p><strong>C</strong><strong>ardiac Electrophysiology</strong></p><p>In a randomized, double-blind, placebo-controlled, 4-way crossover, active comparator study using moxifloxacin in 40</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>healthy subjects, ONGLYZA was not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 40 mg (8 times the MRHD).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>C</u><u>l</u><u>i</u><u>n</u><u>i</u><u>cal efficacy and safety</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>G</u></em><em><u>l</u></em><em><u>ycaemic control</u></em></p><p>&nbsp;</p><p>ONGLYZA has been studied as monotherapy and in combination with metformin, glyburide, and thiazolidinedione</p><p>(pioglitazone and rosiglitazone) therapy.</p><p>&nbsp;</p><p>A total of 4148 patients with type 2 diabetes mellitus were randomized in six, double-blind, controlled clinical trials conducted to evaluate the safety and glycemic efficacy of ONGLYZA. A total of 3021 patients in these trials were treated with ONGLYZA. In these trials, the mean age was 54 years, and 71% of patients were Caucasian, 16% were Asian, 4% were black, and 9% were of other racial groups. An additional 423 patients, including 315 who received ONGLYZA, participated in a placebo-controlled, dose-ranging study of 6 to 12 weeks in duration.</p><p>In these six, double-blind trials, ONGLYZA was evaluated at doses of 2.5 mg and 5 mg once daily. Three of these trials also evaluated a saxagliptin dose of 10 mg daily. The 10 mg daily dose of saxagliptin did not provide greater efficacy</p><p>than the 5 mg daily dose. The 10 mg dosage is not an approved dosage. Treatment with ONGLYZA 5 mg and 2.5 mg</p><p>doses produced clinically relevant and statistically significant improvements in hemoglobin A1c (A1C), fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG) following a standard oral glucose tolerance test (OGTT),</p><p>compared to control. Reductions in A1C were seen across subgroups including gender, age, race, and baseline BMI. ONGLYZA was not associated with significant changes from baseline in body weight or fasting serum lipids compared</p><p>to placebo.</p><p>ONGLYZA has also been evaluated in four additional trials in patients with type 2 diabetes: an active-controlled trial comparing add-on therapy with ONGLYZA to glipizide in 858 patients inadequately controlled on metformin alone, a</p><p>trial comparing ONGLYZA to placebo in 455 patients inadequately controlled on insulin alone or on insulin in</p><p>combination with metformin, a trial comparing ONGLYZA to placebo in 257 patients inadequately controlled on metformin plus a sulfonylurea, and a trial comparing ONGLYZA to placebo in 170 patients with type 2 diabetes and</p><p>moderate or severe renal impairment or ESRD.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin as monotherapy</u></p><p>A total of 766 patients with type 2 diabetes inadequately controlled on diet and exercise (A1C 7% to 10%) participated in two 24-week, double-blind, placebo-controlled trials evaluating the efficacy and safety of ONGLYZA monotherapy.</p><p>In the first trial, following a 2-week single-blind diet, exercise, and placebo lead-in period, 401 patients were randomized</p><p>to 2.5 mg, 5 mg, or 10 mg of ONGLYZA or placebo. The 10 mg dosage is not an approved dosage. Patients who failed to meet specific glycemic goals during the study were treated with metformin rescue therapy, added on to placebo or</p><p>ONGLYZA. Efficacy was evaluated at the last measurement prior to rescue therapy for patients needing rescue. Dose titration of ONGLYZA was not permitted.</p><p>Treatment with ONGLYZA 2.5 mg and 5 mg daily provided significant improvements in A1C, FPG, and PPG compared to placebo (Table 6). The percentage of patients who discontinued for lack of glycemic control or who were rescued for</p><p>meeting prespecified glycemic criteria was 16% in the ONGLYZA 2.5 mg treatment group, 20% in the ONGLYZA 5 mg treatment group, and 26% in the placebo group).</p><p>&nbsp;</p><p><strong>Table 6: Glycemic Parameters at Week 24 in a Placebo-Controlled Study of ONGLYZA Monotherapy in Patients with Type 2 Diabetes*</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA</strong></p><p><strong>2.5 mg</strong></p><p><strong>N</strong><strong>=102</strong></p></td><td style="vertical-align:top"><p><strong>O</strong><strong>N</strong><strong>GL</strong><strong>Y</strong><strong>Z</strong><strong>A</strong></p><p><strong>5 mg</strong></p><p><strong>N</strong><strong>=106</strong></p></td><td style="vertical-align:top"><p><strong>P</strong><strong>l</strong><strong>a</strong><strong>cebo</strong></p><p>&nbsp;</p><p><strong>N</strong><strong>=95</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=100</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=103</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=92</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>7.9</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>+0.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>0.6&Dagger;</p></td><td style="vertical-align:top"><p>0.6&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.9, &minus;0.3)</p></td><td style="vertical-align:top"><p>(&minus;0.9, &minus;0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients achieving A1C &lt;7%</p></td><td style="vertical-align:top"><p>35% (35/100)</p></td><td style="vertical-align:top"><p>38%&sect; (39/103)</p></td><td style="vertical-align:top"><p>24% (22/92)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting Plasma Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=101</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=105</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=92</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>178</p></td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>172</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;15</p></td><td style="vertical-align:top"><p>&minus;9</p></td><td style="vertical-align:top"><p>+6</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;21&sect;</p></td><td style="vertical-align:top"><p>&minus;15&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;31, &minus;10)</p></td><td style="vertical-align:top"><p>(&minus;25, &minus;4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=78</strong></p></td><td style="vertical-align:top"><p><strong>N=84</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=71</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>279</p></td><td style="vertical-align:top"><p>278</p></td><td style="vertical-align:top"><p>283</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;45</p></td><td style="vertical-align:top"><p>&minus;43</p></td><td style="vertical-align:top"><p>&minus;6</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;39&para;</p></td><td style="vertical-align:top"><p>&minus;37&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;61, &minus;16)</p></td><td style="vertical-align:top"><p>(&minus;59, &minus;15)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* &nbsp;&nbsp;&nbsp;&nbsp; Intent-to-treat population using last observation on study or last observation prior to metformin rescue therapy for</p><p>patients needing rescue.</p><p>&dagger; &nbsp;&nbsp;&nbsp;&nbsp; Least squares mean adjusted for baseline value.</p><p>&Dagger; &nbsp;&nbsp;&nbsp;&nbsp; p-value &lt;0.0001 compared to placebo</p><p>&sect; &nbsp;&nbsp;&nbsp;&nbsp; p-value &lt;0.05 compared to placebo</p><p>&para; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significance was not tested for the 2-hour PPG for the 2.5 mg dose of ONGLYZA.</p><p>&nbsp;</p><p>&nbsp;</p><p>A second 24-week monotherapy trial was conducted to assess a range of dosing regimens for ONGLYZA. Treatment-naive patients with inadequately controlled diabetes (A1C 7% to 10%) underwent a 2-week, single-blind diet, exercise, and placebo lead-in period. A total of 365 patients were randomized to 2.5 mg every morning, 5 mg every morning, 2.5 mg</p><p>with possible titration to 5 mg every morning, or 5 mg every evening of ONGLYZA, or placebo. Patients who failed to meet specific glycemic goals during the study were treated with metformin rescue therapy added on to placebo or ONGLYZA; the number of patients randomized per treatment group ranged from 71 to 74.</p><p>Treatment with either ONGLYZA 5 mg every morning or 5 mg every evening provided significant improvements in A1C versus placebo (mean placebo-corrected reductions of 0.4% and 0.3%, respectively). Treatment with ONGLYZA 2.5 mg every morning also provided significant improvement in A1C versus placebo (mean placebo-corrected reduction of</p><p>0.4%).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin add-on to metformin therapy</u></p><p>A total of 743 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ONGLYZA in combination with metformin in patients with inadequate glycemic control (A1C 7% and 10%) on metformin alone. To qualify for enrollment, patients were required to be on a stable dose of metformin (1500-2550 mg daily) for at least 8 weeks.</p><p>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin at their pre-study dose, up to 2500 mg daily. Following the lead-in period, eligible patients were randomized to 2.5 mg, 5 mg, or 10 mg of ONGLYZA or placebo in addition to their current dose of open-label metformin. The 10 mg dosage is not an approved dosage. Patients who failed to meet specific glycemic goals during the study were treated with pioglitazone rescue therapy, added on to existing study medications. Dose titrations of ONGLYZA and metformin were not permitted.</p><p>ONGLYZA 2.5 mg and 5 mg add-on to metformin provided significant improvements in A1C, FPG, and PPG compared with placebo add-on to metformin (Table 7). Mean changes from baseline for A1C over time and at endpoint are shown in</p><p>Figure 1. The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting</p><p>prespecified glycemic criteria was 15% in the ONGLYZA 2.5 mg add-on to metformin group, 13% in the ONGLYZA 5 mg add-on to metformin group, and 27% in the placebo add-on to metformin group.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 7: Glycemic Parameters at Week 24 in a Placebo-Controlled Study of ONGLYZA as Add-On Combination</strong></p><p><strong>Therapy with Metformin*</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 2.5 mg</strong></p><p><strong>+ Metformin</strong></p><p><strong>N=192</strong></p></td><td style="vertical-align:top"><p><strong>O</strong><strong>N</strong><strong>GL</strong><strong>Y</strong><strong>Z</strong><strong>A 5 mg</strong></p><p><strong>+ Metformin</strong></p><p><strong>N=191</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+ Metformin</strong></p><p><strong>N</strong><strong>=179</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N=186</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=186</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=175</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.1</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.6</p></td><td style="vertical-align:top"><p>&minus;0.7</p></td><td style="vertical-align:top"><p>+0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.7&Dagger;</p></td><td style="vertical-align:top"><p>&minus;0.8&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.9, &minus;0.5)</p></td><td style="vertical-align:top"><p>(&minus;1.0, &minus;0.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients achieving A1C &lt;7%</p></td><td style="vertical-align:top"><p>37%&sect; (69/186)</p></td><td style="vertical-align:top"><p>44%&sect; (81/186)</p></td><td style="vertical-align:top"><p>17% (29/175)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting Plasma Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=188</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=187</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=176</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>174</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>175</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>+1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;16&sect;</p></td><td style="vertical-align:top"><p>&minus;23&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;23, &minus;9)</p></td><td style="vertical-align:top"><p>(&minus;30, &minus;16)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=155</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=155</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=135</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>294</p></td><td style="vertical-align:top"><p>296</p></td><td style="vertical-align:top"><p>295</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;62</p></td><td style="vertical-align:top"><p>&minus;58</p></td><td style="vertical-align:top"><p>&minus;18</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;44&sect;</p></td><td style="vertical-align:top"><p>&minus;40&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;60, &minus;27)</p></td><td style="vertical-align:top"><p>(&minus;56, &minus;24)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study or last observation prior to pioglitazone rescue therapy for patients needing rescue.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.0001 compared to placebo + metformin</p><p>&sect;&nbsp;&nbsp; &nbsp;p-value &lt;0.05 compared to placebo + metformin</p><p>&nbsp;</p><p><strong>Figure 1: Mean Change from Baseline in A1C in a Placebo-Controlled Trial of ONGLYZA as Add-On</strong></p><p><strong>Combination Therapy with Metformin*</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="845" height="578" vspace="0" hspace="0" border="0" style="width:845px;height:578px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>* Includes patients with a baseline and week 24 value.</p><p>Week 24 (LOCF) includes intent-to-treat population using last observation on study prior to pioglitazone rescue therapy for patients needing rescue. Mean change from baseline is adjusted for baseline value.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin add-on to metformin compared with SU add-on to metformin</u></p><p>&nbsp;</p><p>In this 52-week, active-controlled trial, a total of 858 patients with type 2 diabetes and inadequate glycemic control (A1C</p><p>&gt;6.5% and 10%) on metformin alone were randomized to double-blind add-on therapy with ONGLYZA or glipizide. Patients were required to be on a stable dose of metformin (at least 1500 mg daily) for at least 8 weeks prior to enrollment.</p><p>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin (1500-3000 mg based on their pre-study dose). Following the lead-in period,</p><p>eligible patients were randomized to 5 mg of ONGLYZA or 5 mg of glipizide in addition to their current dose of open- label metformin. Patients in the glipizide plus metformin group underwent blinded titration of the glipizide dose during the</p><p>first 18 weeks of the trial up to a maximum glipizide dose of 20 mg per day. Titration was based on a goal FPG &le;110 mg/dL or the highest tolerable glipizide dose. Fifty percent (50%) of the glipizide-treated patients were titrated to the 20-</p><p>mg daily dose; 21% of the glipizide-treated patients had a final daily glipizide dose of 5 mg or less. The mean final daily dose of glipizide was 15 mg.</p><p>After 52 weeks of treatment, ONGLYZA and glipizide resulted in similar mean reductions from baseline in A1C when added to metformin therapy (Table 8). This conclusion may be limited to patients with baseline A1C comparable to those</p><p>in the trial (91% of patients had baseline A1C &lt;9%).</p><p>From a baseline mean body weight of 89 kg, there was a statistically significant mean reduction of 1.1 kg in patients treated with ONGLYZA compared to a mean weight gain of 1.1 kg in patients treated with glipizide (p&lt;0.0001).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 8: Glycemic Parameters at Week 52 in an Active-Controlled Trial of ONGLYZA versus Glipizide in</strong></p><p><strong>Combination with Metformin</strong>*</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 5 mg</strong></p><p><strong>+ Metformin</strong></p><p><strong>N=428</strong></p></td><td style="vertical-align:top"><p><strong>Titrated Glipizide</strong></p><p><strong>+ Metformin</strong></p><p><strong>N=430</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N=423</strong></p></td><td style="vertical-align:top"><p><strong>N=423</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>7.6</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.6</p></td><td style="vertical-align:top"><p>&minus;0.7</p></td></tr><tr><td style="vertical-align:top"><p>Difference from glipizide + metformin (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.02, 0.2)&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting Plasma Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=420</strong></p></td><td style="vertical-align:top"><p><strong>N=420</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>161</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;9</p></td><td style="vertical-align:top"><p>&minus;16</p></td></tr><tr><td style="vertical-align:top"><p>Difference from glipizide + metformin (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(2, 11)&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;ONGLYZA + metformin is considered non-inferior to glipizide + metformin because the upper limit of this confidence interval is less than the prespecified non-inferiority margin of 0.35%.</p><p>&sect;&nbsp;&nbsp; &nbsp;Significance not tested.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin in combination with metformin as initial therapy</u></p><p>A total of 1306 treatment-naive patients with type 2 diabetes mellitus participated in this 24-week, randomized, double- blind, active-controlled trial to evaluate the efficacy and safety of ONGLYZA coadministered with metformin in patients with inadequate glycemic control (A1C 8% to 12%) on diet and exercise alone. Patients were required to be treatment- naive to be enrolled in this study.</p><p>Patients who met eligibility criteria were enrolled in a single-blind, 1-week, dietary and exercise placebo lead-in period. Patients were randomized to one of four treatment arms: ONGLYZA 5 mg + metformin 500 mg, saxagliptin 10 mg + metformin 500 mg, saxagliptin 10 mg + placebo, or metformin 500 mg + placebo. The 10 mg dosage is not an approved dosage. ONGLYZA was dosed once daily. In the 3 treatment groups using metformin, the metformin dose was up-titrated weekly in 500 mg per day increments, as tolerated, to a maximum of 2000 mg per day based on FPG. Patients who failed to meet specific glycemic goals during the studies were treated with pioglitazone rescue as add-on therapy. Coadministration of ONGLYZA 5 mg plus metformin provided significant improvements in A1C, FPG, and PPG compared with placebo plus metformin (Table 9).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 9: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of ONGLYZA Coadministration with</strong></p><p><strong>Metformin in Treatment-Naive Patients*</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 5 mg</strong></p><p><strong>+ Metformin</strong></p><p><strong>N</strong><strong>=320</strong></p></td><td style="vertical-align:top"><p><strong>P</strong><strong>l</strong><strong>a</strong><strong>cebo</strong></p><p><strong>+ Metformin</strong></p><p><strong>N</strong><strong>=328</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=306</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=313</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>9.4</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;2.5</p></td><td style="vertical-align:top"><p>&minus;2.0</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.5&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.7, &minus;0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients achieving A1C &lt;7%</p></td><td style="vertical-align:top"><p>60%&sect; (185/307)</p></td><td style="vertical-align:top"><p>41% (129/314)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting Plasma Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=315</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=320</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>199</p></td><td style="vertical-align:top"><p>199</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;60</p></td><td style="vertical-align:top"><p>&minus;47</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;13&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;19, &minus;6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=146</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=141</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>340</p></td><td style="vertical-align:top"><p>355</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;138</p></td><td style="vertical-align:top"><p>&minus;97</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;41&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;57, &minus;25)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study or last observation prior to pioglitazone rescue therapy for patients needing rescue.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.0001 compared to placebo + metformin</p><p>&sect;&nbsp;&nbsp; &nbsp;p-value &lt;0.05 compared to placebo + metformin</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin add-on to glyburide therapy</u></p><p>A total of 768 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ONGLYZA in combination with a sulfonylurea (SU) in patients with inadequate glycemic control at enrollment (A1C 7.5% to 10%) on a submaximal dose of SU alone. To qualify for enrollment, patients were required to be on a submaximal dose of SU for 2 months or greater. In this study, ONGLYZA in combination with a fixed, intermediate dose of SU was compared to titration to a higher dose of SU.</p><p>Patients who met eligibility criteria were enrolled in a single-blind, 4-week, dietary and exercise lead-in period, and placed on glyburide 7.5 mg once daily. Following the lead-in period, eligible patients with A1C 7% to 10% were randomized to either 2.5 mg or 5 mg of ONGLYZA add-on to 7.5 mg glyburide or to placebo plus a 10 mg total daily dose of glyburide. Patients who received placebo were eligible to have glyburide up-titrated to a total daily dose of 15 mg. Up-titration of glyburide was not permitted in patients who received ONGLYZA 2.5 mg or 5 mg. Glyburide could be down-titrated in any treatment group once during the 24-week study period due to hypoglycemia as deemed necessary by the investigator. Approximately 92% of patients in the placebo plus glyburide group were up-titrated to a final total daily dose of 15 mg during the first 4 weeks of the study period. Patients who failed to meet specific glycemic goals during the study were treated with metformin rescue, added on to existing study medication. Dose titration of ONGLYZA was not permitted during the study.</p><p>In combination with glyburide, ONGLYZA 2.5 mg and 5 mg provided significant improvements in A1C, FPG, and PPG</p><p>compared with the placebo plus up-titrated glyburide group (Table 10). The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 18% in the ONGLYZA 2.5</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>mg add-on to glyburide group, 17% in the ONGLYZA 5 mg add-on to glyburide group, and 30% in the placebo plus up- titrated glyburide group.</p><p>&nbsp;</p><p><strong>Table 10: Glycemic Parameters at Week 24 in a Placebo-Controlled Study of ONGLYZA as Add-On Combination</strong></p><p><strong>Therapy with Glyburide*</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA</strong></p><p><strong>2</strong><strong>.</strong><strong>5 mg</strong></p><p><strong>+ Glyburide</strong></p><p><strong>7</strong><strong>.</strong><strong>5 mg</strong></p><p><strong>N=248</strong></p></td><td style="vertical-align:top"><p><strong>O</strong><strong>N</strong><strong>GL</strong><strong>Y</strong><strong>Z</strong><strong>A</strong></p><p><strong>5 mg</strong></p><p><strong>+ Glyburide</strong></p><p><strong>7.5 mg</strong></p><p><strong>N=253</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>&nbsp;</p><p><strong>+</strong></p><p><strong>Up-Titrated</strong></p><p><strong>Glyburide</strong></p><p><strong>N=267</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N=246</strong></p></td><td style="vertical-align:top"><p><strong>N=250</strong></p></td><td style="vertical-align:top"><p><strong>N=264</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>8.4</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.5</p></td><td style="vertical-align:top"><p>&minus;0.6</p></td><td style="vertical-align:top"><p>+0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from up-titrated glyburide (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.6&Dagger;</p></td><td style="vertical-align:top"><p>&minus;0.7&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.8, &minus;0.5)</p></td><td style="vertical-align:top"><p>(&minus;0.9, &minus;0.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients achieving A1C &lt;7%</p></td><td style="vertical-align:top"><p>22%&sect; (55/246)</p></td><td style="vertical-align:top"><p>23%&sect; (57/250)</p></td><td style="vertical-align:top"><p>9% (24/264)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting Plasma Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N=247</strong></p></td><td style="vertical-align:top"><p><strong>N=252</strong></p></td><td style="vertical-align:top"><p><strong>N=265</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>170</p></td><td style="vertical-align:top"><p>175</p></td><td style="vertical-align:top"><p>174</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;7</p></td><td style="vertical-align:top"><p>&minus;10</p></td><td style="vertical-align:top"><p>+1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from up-titrated glyburide (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;8&sect;</p></td><td style="vertical-align:top"><p>&minus;10&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;14, &minus;1)</p></td><td style="vertical-align:top"><p>(&minus;17, &minus;4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2</strong><strong>-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=195</strong></p></td><td style="vertical-align:top"><p><strong>N=202</strong></p></td><td style="vertical-align:top"><p><strong>N=206</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>309</p></td><td style="vertical-align:top"><p>315</p></td><td style="vertical-align:top"><p>323</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;31</p></td><td style="vertical-align:top"><p>&minus;34</p></td><td style="vertical-align:top"><p>+8</p></td></tr><tr><td style="vertical-align:top"><p>Difference from up-titrated glyburide (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;38&sect;</p></td><td style="vertical-align:top"><p>&minus;42&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;50, &minus;27)</p></td><td style="vertical-align:top"><p>(&minus;53, &minus;31)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study or last observation prior to metformin rescue therapy for patients needing rescue.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.0001 compared to placebo + up-titrated glyburide</p><p>&sect;&nbsp;&nbsp; &nbsp;p-value &lt;0.05 compared to placebo + up-titrated glyburide</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin add-on combination therapy with insulin (with or without metformin)</u></p><p>A total of 455 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ONGLYZA in combination with insulin in patients with inadequate glycemic control (A1C 7.5% and 11%) on insulin alone (N=141) or on insulin in combination with a stable dose of metformin (N=314). Patients were required to be on a stable dose of insulin (30 units to &le;150 units daily) with &le;20% variation in total daily dose for 8 weeks prior to screening. Patients entered the trial on intermediate- or long-acting (basal) insulin or premixed insulin. Patients using short-acting insulins were excluded unless the short-acting insulin was administered as part of a premixed insulin.</p><p>Patients who met eligibility criteria were enrolled in a single-blind, four-week, dietary and exercise placebo lead-in period during which patients received insulin (and metformin if applicable) at their pretrial dose(s). Following the lead-in period, eligible patients were randomized to add-on therapy with either ONGLYZA 5 mg or placebo. Doses of the antidiabetic therapies were to remain stable but patients were rescued and allowed to adjust the insulin regimen if specific glycemic goals were not met or if the investigator learned that the patient had self-increased the insulin dose by &gt;20%. Data after rescue were excluded from the primary efficacy analyses.</p><p>Add-on therapy with ONGLYZA 5 mg provided significant improvements from baseline to Week 24 in A1C and PPG</p><p>compared with add-on placebo (Table 11). Similar mean reductions in A1C versus placebo were observed for patients</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>using ONGLYZA 5 mg add-on to insulin alone and ONGLYZA 5 mg add-on to insulin in combination with metformin (&minus;0.4% and &minus;0.4%, respectively). The percentage of patients who discontinued for lack of glycemic control or who were rescued was 23% in the ONGLYZA group and 32% in the placebo group.</p><p>The mean daily insulin dose at baseline was 53 units in patients treated with ONGLYZA 5 mg and 55 units in patients treated with placebo. The mean change from baseline in daily dose of insulin was 2 units for the ONGLYZA 5 mg group</p><p>and 5 units for the placebo group.</p><p>&nbsp;</p><p><strong>Table 11: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of ONGLYZA as Add-On Combination</strong></p><p><strong>Therapy with Insulin</strong>*</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 5 mg</strong></p><p><strong>+ Insulin</strong></p><p><strong>(+/&minus; Metformin)</strong></p><p><strong>N</strong><strong>=304</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+ Insulin</strong></p><p><strong>(</strong><strong>+/&minus; Metformin)</strong></p><p><strong>N=151</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=300</strong></p></td><td style="vertical-align:top"><p><strong>N=149</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>8.7</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.7</p></td><td style="vertical-align:top"><p>&minus;0.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.4&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.6, &minus;0.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=262</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=129</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>251</p></td><td style="vertical-align:top"><p>255</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;27</p></td><td style="vertical-align:top"><p>&minus;4</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;23&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;37, &minus;9)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study or last observation prior to insulin rescue therapy for patients needing rescue.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value and metformin use at baseline.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.0001 compared to placebo + insulin</p><p>&sect;&nbsp;&nbsp; &nbsp;p-value &lt;0.05 compared to placebo + insulin</p><p>&nbsp;</p><p>The change in fasting plasma glucose from baseline to Week 24 was also tested, but was not statistically significant. The percent of patients achieving an A1C &lt;7% was 17% (52/300) with ONGLYZA in combination with insulin compared to</p><p>7% (10/149) with placebo. Significance was not tested.</p><p>&nbsp;</p><p><u>Saxagliptin add-on to thiazolidinedione therapy</u></p><p>A total of 565 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ONGLYZA in combination with a thiazolidinedione (TZD) in patients with inadequate glycemic control (A1C 7% to 10.5%) on TZD alone. To qualify for enrollment, patients were required to be</p><p>on a stable dose of pioglitazone (30-45 mg once daily) or rosiglitazone (4 mg once daily or 8 mg either once daily or in two divided doses of 4 mg) for at least 12 weeks.</p><p>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received TZD at their pre-study dose. Following the lead-in period, eligible patients were</p><p>randomized to 2.5 mg or 5 mg of ONGLYZA or placebo in addition to their current dose of TZD. Patients who failed to meet specific glycemic goals during the study were treated with metformin rescue, added on to existing study medications.</p><p>Dose titration of ONGLYZA or TZD was not permitted during the study. A change in TZD regimen from rosiglitazone to pioglitazone at specified, equivalent therapeutic doses was permitted at the investigator&rsquo;s discretion if believed to be</p><p>medically appropriate.</p><p>ONGLYZA 2.5 mg and 5 mg add-on to TZD provided significant improvements in A1C, FPG, and PPG compared with placebo add-on to TZD (Table 12). The proportion of patients who discontinued for lack of glycemic control or who were</p><p>rescued for meeting prespecified glycemic criteria was 10% in the ONGLYZA 2.5 mg add-on to TZD group, 6% for the</p><p>ONGLYZA 5 mg add-on to TZD group, and 10% in the placebo add-on to TZD group.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 12: Glycemic Parameters at Week 24 in a Placebo-Controlled Study of ONGLYZA as Add-On Combination</strong></p><p><strong>Therapy with a Thiazolidinedione*</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 2.5 mg</strong></p><p><strong>+ TZD</strong></p><p><strong>N</strong><strong>=195</strong></p></td><td style="vertical-align:top"><p><strong>O</strong><strong>N</strong><strong>GL</strong><strong>Y</strong><strong>Z</strong><strong>A 5 mg</strong></p><p><strong>+ TZD</strong></p><p><strong>N=186</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+ TZD</strong></p><p><strong>N=184</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=192</strong></p></td><td style="vertical-align:top"><p><strong>N=183</strong></p></td><td style="vertical-align:top"><p><strong>N=180</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>8.2</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.7</p></td><td style="vertical-align:top"><p>&minus;0.9</p></td><td style="vertical-align:top"><p>&minus;0.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.4&sect;</p></td><td style="vertical-align:top"><p>&minus;0.6&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.6, &minus;0.2)</p></td><td style="vertical-align:top"><p>(&minus;0.8, &minus;0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients achieving A1C &lt;7%</p></td><td style="vertical-align:top"><p>42%&sect; (81/192)</p></td><td style="vertical-align:top"><p>42%&sect; (77/184)</p></td><td style="vertical-align:top"><p>26% (46/180)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting Plasma Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=193</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=185</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=181</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>163</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>162</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;14</p></td><td style="vertical-align:top"><p>&minus;17</p></td><td style="vertical-align:top"><p>&minus;3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;12&sect;</p></td><td style="vertical-align:top"><p>&minus;15&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;20, &minus;3)</p></td><td style="vertical-align:top"><p>(&minus;23, &minus;6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=156</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=134</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=127</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>296</p></td><td style="vertical-align:top"><p>303</p></td><td style="vertical-align:top"><p>291</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;55</p></td><td style="vertical-align:top"><p>&minus;65</p></td><td style="vertical-align:top"><p>&minus;15</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;40&sect;</p></td><td style="vertical-align:top"><p>&minus;50&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;56, &minus;24)</p></td><td style="vertical-align:top"><p>(&minus;66, &minus;34)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study or last observation prior to metformin rescue therapy for patients needing rescue.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.0001 compared to placebo + TZD</p><p>&sect;&nbsp;&nbsp; &nbsp;p-value &lt;0.05 compared to placebo + TZD</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Saxagliptin add-on combination therapy with metformin and sulphonylurea</u></p><p>A total of 257 patients with type 2 diabetes participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ONGLYZA in combination with metformin plus a sulfonylurea in patients with inadequate glycemic control (A1C 7% and 10%). Patients were to be on a stable combined dose of metformin extended- release or immediate-release (at maximum tolerated dose, with minimum dose for enrollment being 1500 mg) and a sulfonylurea (at maximum tolerated dose, with minimum dose for enrollment being 50% of the maximum recommended dose) for 8 weeks prior to enrollment.</p><p>Patients who met eligibility criteria were entered in a 2-week enrollment period to allow assessment of inclusion/exclusion criteria. Following the 2-week enrollment period, eligible patients were randomized to either double-blind ONGLYZA (5 mg once daily) or double-blind matching placebo for 24 weeks. During the 24-week double-blind treatment period,</p><p>patients were to receive metformin and a sulfonylurea at the same constant dose ascertained during enrollment. Sulfonylurea dose could be down titrated once in the case of a major hypoglycemic event or recurring minor hypoglycemic</p><p>events. In the absence of hypoglycemia, titration (up or down) of study medication during the treatment period was</p><p>prohibited.</p><p>ONGLYZA in combination with metformin plus a sulfonylurea provided significant improvements in A1C and PPG</p><p>compared with placebo in combination with metformin plus a sulfonylurea (Table 13). The percentage of patients who discontinued for lack of glycemic control was 6% in the ONGLYZA group and 5% in the placebo group.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 13: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of ONGLYZA as Add-On Combination</strong></p><p><strong>Therapy with Metformin plus Sulfonylurea</strong>*</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 5 mg</strong></p><p><strong>+ Metformin plus</strong></p><p><strong>Sulfonylurea</strong></p><p><strong>N</strong><strong>=129</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+ Metformin plus</strong></p><p><strong>Sulfonylurea</strong></p><p><strong>N</strong><strong>=128</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=127</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=127</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>8.2</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.7</p></td><td style="vertical-align:top"><p>&minus;0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.7&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.9, &minus;0.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour Postprandial Glucose (mg/dL)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=115</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=113</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>268</p></td><td style="vertical-align:top"><p>262</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;12</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;17&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;32, &minus;2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation prior to discontinuation.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.0001 compared to placebo + metformin plus sulfonylurea</p><p>&sect;&nbsp;&nbsp; &nbsp;p-value &lt;0.05 compared to placebo + metformin plus sulfonylurea</p><p>&nbsp;</p><p>The change in fasting plasma glucose from baseline to Week 24 was also tested, but was not statistically significant. The percent of patients achieving an A1C &lt;7% was 31% (39/127) with ONGLYZA in combination with metformin plus a sulfonylurea compared to 9% (12/127) with placebo. Significance was not tested.</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>A total of 170 patients participated in a 12-week, randomized, double-blind, placebo-controlled trial conducted to evaluate the efficacy and safety of ONGLYZA 2.5 mg once daily compared with placebo in patients with type 2 diabetes and</p><p>moderate (n=90) or severe (n=41) renal impairment or ESRD (n=39). In this trial, 98% of the patients were using background antidiabetic medications (75% were using insulin and 31% were using oral antidiabetic medications, mostly</p><p>sulfonylureas).</p><p>After 12 weeks of treatment, ONGLYZA 2.5 mg provided significant improvement in A1C compared to placebo (Table</p><p>14). In the subgroup of patients with ESRD, ONGLYZA and placebo resulted in comparable reductions in A1C from baseline to Week 12. This finding is inconclusive because the trial was not adequately powered to show efficacy within</p><p>specific subgroups of renal impairment.</p><p>After 12 weeks of treatment, the mean change in FPG was &minus;12 mg/dL with ONGLYZA 2.5 mg and &minus;13 mg/dL with placebo. Compared to placebo, the mean change in FPG with ONGLYZA was &minus;12 mg/dL in the subgroup of patients with</p><p>moderate renal impairment, &minus;4 mg/dL in the subgroup of patients with severe renal impairment, and +44 mg/dL in the</p><p>subgroup of patients with ESRD. These findings are inconclusive because the trial was not adequately powered to show efficacy within specific subgroups of renal impairment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 14: A1C at Week 12 in a Placebo-Controlled Trial of ONGLYZA in Patients with Renal Impairment</strong>*</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>ONGLYZA 2.5 mg</strong></p><p><strong>N=85</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=85</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hemoglobin A1C (%)</strong></p></td><td style="vertical-align:top"><p><strong>N=81</strong></p></td><td style="vertical-align:top"><p><strong>N=83</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>8.1</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.9</p></td><td style="vertical-align:top"><p>&minus;0.4</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean&dagger;)</p></td><td style="vertical-align:top"><p>&minus;0.4&Dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95% Confidence Interval</p></td><td style="vertical-align:top"><p>(&minus;0.7, &minus;0.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Intent-to-treat population using last observation on study.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares mean adjusted for baseline value.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p-value &lt;0.01 compared to placebo</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and effectiveness of ONGLYZA in pediatric patients under 18 years of age have not been established. Additionally, studies characterizing the pharmacokinetics of ONGLYZA in pediatric patients have not been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of saxagliptin and its active metabolite, 5-hydroxy saxagliptin were similar in healthy subjects and in patients with type 2 diabetes mellitus. The Cmax &nbsp;and AUC values of saxagliptin and its active metabolite increased proportionally in the 2.5 to 400 mg dose range. Following a 5 mg single oral dose of saxagliptin to healthy subjects, the mean plasma AUC values for saxagliptin and its active metabolite were 78 ngh/mL and 214 ngh/mL, respectively. The corresponding plasma Cmax &nbsp;values were 24 ng/mL and 47 ng/mL, respectively. The average variability (%CV) for AUC and Cmax &nbsp;for both saxagliptin and its active metabolite was less than 25%.</p><p>No appreciable accumulation of either saxagliptin or its active metabolite was observed with repeated once-daily dosing at</p><p>any dose level. No dose- and time-dependence were observed in the clearance of saxagliptin and its active metabolite over</p><p>14 days of once-daily dosing with saxagliptin at doses ranging from 2.5 to 400 mg</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>The median time to maximum concentration (Tmax) following the 5 mg once daily dose was 2 hours for saxagliptin and 4 hours for its active metabolite. Administration with a high-fat meal resulted in an increase in Tmax &nbsp;of saxagliptin by approximately 20 minutes as compared to fasted conditions. There was a 27% increase in the AUC of saxagliptin when given with a meal as compared to fasted conditions. ONGLYZA may be administered with or without food</p><p>&nbsp;</p><p><u>Interaction with food</u></p><p>&nbsp;</p><p>Food had relatively modest effects on the pharmacokinetics of saxagliptin in healthy subjects. Administration with food (a high-fat meal) resulted in no change in saxagliptin Cmax and a 27% increase in AUC compared with the fasted state. The time for saxagliptin to reach Cmax (Tmax) was increased by approximately 0.5 hours with food compared with the fasted state. These changes were not considered to be clinically meaningful.</p><p>&nbsp;</p><p><u>D</u><u>i</u><u>s</u><u>t</u><u>r</u><u>i</u><u>bution</u></p><p>&nbsp;</p><p>The <em>in vitro </em>protein binding of saxagliptin and its major metabolite in human serum is negligible. Thus, changes in blood protein levels in various disease states (e.g. renal or hepatic impairment) are not expected to alter the disposition of saxagliptin.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>The biotransformation of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). The major metabolite of saxagliptin is also a DPP4 inhibitor, which is one-half as potent as saxagliptin. Therefore, strong CYP3A4/5 inhibitors</p><p>and inducers will alter the pharmacokinetics of saxagliptin and its active metabolite (<em>see <u>section 4.5)</u></em>.</p><p>&nbsp;</p><p><u>El</u><u>i</u><u>m</u><u>i</u><u>nation</u></p><p>Saxagliptin is eliminated by both renal and hepatic pathways. Following a single 50 mg dose of 14C-saxagliptin, 24%, 36%, and 75% of the dose was excreted in the urine as saxagliptin, its active metabolite, and total radioactivity, respectively. The</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>average renal clearance of saxagliptin (230 mL/min) was greater than the average estimated glomerular filtration rate (120 mL/min), suggesting some active renal excretion. A total of 22% of the administered radioactivity was recovered in feces representing the fraction of the saxagliptin dose excreted in bile and/or unabsorbed drug from the gastrointestinal tract. Following a single oral dose of ONGLYZA 5 mg to healthy subjects, the mean plasma terminal half-life (t1/2) for saxagliptin and its active metabolite was 2.5 and 3.1 hours, respectively.</p><p>&nbsp;</p><p><u>Linearity</u></p><p>&nbsp;</p><p>The Cmax and AUC of saxagliptin and its major metabolite increased proportionally to the saxagliptin dose. No appreciable accumulation of either saxagliptin or its major metabolite was observed with repeated once-daily dosing at any dose level. No dose- and time-dependence was observed in the clearance of saxagliptin and its major metabolite over 14 days of once-daily dosing with saxagliptin at doses ranging from 2.5 mg to 400 mg.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>Renal impairment</u></p><p>A single-dose, open-label study was conducted to evaluate the pharmacokinetics of saxagliptin (10 mg dose) in subjects with varying degrees of chronic renal impairment (N=8 per group) compared to subjects with normal renal function. The</p><p>10 mg dosage is not an approved dosage. The study included patients with renal impairment classified on the basis of creatinine clearance as mild (&gt;50 to 80 mL/min), moderate (30 to 50 mL/min), and severe (&lt;30 mL/min), as well as patients with end-stage renal disease on hemodialysis. Creatinine clearance was estimated from serum creatinine based on the Cockcroft-Gault formula:</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:73.25pt;
 margin-top:13.55pt;width:157.55pt;height:.1pt;z-index:-3836;
 mso-position-horizontal-relative:page' coordorigin="1465,271" coordsize="3151,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1465;top:271;width:3151;
  height:2' coordorigin="1465,271" coordsize="3151,0" path="m1465,271r3151,e"
  filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="212" height="2" src="file:///C:/Users/ktzc827/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />CrCl = [140  age (years)] &times; weight (kg) {&times; 0.85 for female patients} [72 &times; serum creatinine (mg/dL)]</p><p>&nbsp;</p><p>The degree of renal impairment did not affect the Cmax of saxagliptin or its active metabolite. In subjects with mild renal impairment, the AUC values of saxagliptin and its active metabolite were 20% and 70% higher, respectively, than AUC values in subjects with normal renal function. Because increases of this magnitude are not considered to be clinically relevant, dosage adjustment in patients with mild renal impairment is not recommended. In subjects with moderate or severe renal impairment, the AUC values of saxagliptin and its active metabolite were up to 2.1- and 4.5-fold higher, respectively, than AUC values in subjects with normal renal function. To achieve plasma exposures of saxagliptin and its active metabolite similar to those in patients with normal renal function, the recommended dose is 2.5 mg once daily in patients with moderate and severe renal impairment, as well as in patients with end-stage renal disease requiring hemodialysis. Saxagliptin is removed by hemodialysis</p><p>&nbsp;</p><p><u>H</u><u>epatic impairment</u></p><p>In subjects with hepatic impairment (Child-Pugh classes A, B, and C), mean Cmax &nbsp;and AUC of saxagliptin were up to 8%</p><p>and 77% higher, respectively, compared to healthy matched controls following administration of a single 10 mg dose of</p><p>saxagliptin. The 10 mg dosage is not an approved dosage. The corresponding Cmax &nbsp;and AUC of the active metabolite were up to 59% and 33% lower, respectively, compared to healthy matched controls. These differences are not considered to be</p><p>clinically meaningful. No dosage adjustment is recommended for patients with hepatic impairment.</p><p><strong><em>B</em></strong><strong><em>ody Mass Index</em></strong></p><p>No dosage adjustment is recommended based on body mass index (BMI) which was not identified as a significant covariate on the apparent clearance of saxagliptin or its active metabolite in the population pharmacokinetic analysis</p><p><strong><em>Gender</em></strong></p><p>No dosage adjustment is recommended based on gender. There were no differences observed in saxagliptin pharmacokinetics between males and females. Compared to males, females had approximately 25% higher exposure values</p><p>for the active metabolite than males, but this difference is unlikely to be of clinical relevance. Gender was not identified as a significant covariate on the apparent clearance of saxagliptin and its active metabolite in the population pharmacokinetic</p><p>analysis.</p><p>&nbsp;</p><p><u>Elderly (&ge; 65 years)</u></p><p>No dosage adjustment is recommended based on age alone. Elderly subjects (65-80 years) had 23% and 59% higher geometric mean Cmax and geometric mean AUC values, respectively, for saxagliptin than young subjects (18-40 years).</p><p>Differences in active metabolite pharmacokinetics between elderly and young subjects generally reflected the differences observed in saxagliptin pharmacokinetics. The difference between the pharmacokinetics of saxagliptin and the active</p><p>metabolite in young and elderly subjects is likely due to multiple factors including declining renal function and metabolic capacity with increasing age. Age was not identified as a significant covariate on the apparent clearance of saxagliptin and</p><p>its active metabolite in the population pharmacokinetic analysis.</p><p><strong><em>Race and Ethnicity</em></strong></p><p>No dosage adjustment is recommended based on race. The population pharmacokinetic analysis compared the pharmacokinetics of saxagliptin and its active metabolite in 309 Caucasian subjects with 105 non-Caucasian subjects</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(consisting of six racial groups). No significant difference in the pharmacokinetics of saxagliptin and its active metabolite were detected between these two populations.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis</strong></p><p>&nbsp;</p><p>Saxagliptin did not induce tumors in either mice (50, 250, and 600 mg/kg) or rats (25, 75, 150, and 300 mg/kg) at the highest doses evaluated. The highest doses evaluated in mice were equivalent to approximately 870 (males) and 1165 (females) times the human exposure at the MRHD of 5 mg/day. In rats, exposures were approximately 355 (males) and</p><p>2217 (females) times the MRHD.</p><p>&nbsp;</p><p><strong>Mutagenesis</strong></p><p>&nbsp;</p><p>Saxagliptin was not mutagenic or clastogenic with or without metabolic activation in an in vitro Ames bacterial assay, an</p><p>in vitro cytogenetics assay in primary human lymphocytes, an in vivo oral micronucleus assay in rats, an in vivo oral DNA</p><p>repair study in rats, and an oral in vivo/in vitro cytogenetics study in rat peripheral blood lymphocytes. The active metabolite was not mutagenic in an in vitro Ames bacterial assay.</p><p>&nbsp;</p><p><strong>Impairment of Fertility</strong></p><p>&nbsp;</p><p>In a rat fertility study, males were treated with oral gavage doses for 2 weeks prior to mating, during mating, and up to scheduled termination (approximately 4 weeks total) and females were treated with oral gavage doses for 2 weeks prior to mating through gestation day 7. No adverse effects on fertility were observed at exposures of approximately 603 (males) and 776 (females) times the MRHD. Higher doses that elicited maternal toxicity also increased fetal resorptions (approximately 2069 and 6138 times the MRHD). Additional effects on estrous cycling, fertility, ovulation, and implantation were observed at approximately 6138 times the MRHD.</p><p>&nbsp;</p><p><strong>Animal Toxicology and/or Pharmacology</strong></p><p>Saxagliptin produced adverse skin changes in the extremities of cynomolgus monkeys (scabs and/or ulceration of tail, digits, scrotum, and/or nose). Skin lesions were reversible at &ge;20 times the MRHD but in some cases were irreversible and</p><p>necrotizing at higher exposures. Adverse skin changes were not observed at exposures similar to (1 to 3 times) the MRHD</p><p>of 5 mg. Clinical correlates to skin lesions in monkeys have not been observed in human clinical trials of saxagliptin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>T</u><u>a</u><u>b</u><u>l</u><u>e</u><u>t core:</u></p><p>&nbsp;</p><p>Lactose monohydrate</p><p>&nbsp;</p><p>Cellulose, microcrystalline (E460i)</p><p>Croscarmellose sodium (E468)</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Fil</u><u>m</u><u>-coat</u><u>i</u><u>ng:</u></p><p>Polyvinyl alcohol Macrogol 3350</p><p>Titanium dioxide (E171)</p><p>Talc (E553b)</p><p>Iron oxide red (E172) <em>5 mg Tablets only</em></p><p>&nbsp;</p><p>Iron oxide yellow (E172) <em>2.5 mg Tablets </em></p><p><em>only &nbsp;</em>&nbsp;<u>Printing ink:</u></p><p>Shellac</p><p>&nbsp;</p><p>Indigo carmine aluminium lake (E132)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>o</sup>C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2.5 mg Tablets</p><p>Pack sizes of 30 film-coated tablets Primary Packaging: Bottle Secondary Packaging: Carton</p><p>5mg Tablets</p><p>Pack sizes of 30 film-coated tablets</p><p>Primary Packaging: Bottle</p><p>Secondary Packaging: Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
AstraZeneca AB SE-151 85
Södertälje, Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
May 2018

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>